Document:

Memorandum
of Understanding

Governing
the License of Intellectual Property

 

And

 

Manufacturing,
Sales

and Distribution of
Gradium

 

Between

 

LightPath Technologies,
Inc.

 

And

 

Hubei, New Hua Guang
Information Materials

Company, Ltd.

 

Effective
Date: September19, 2012

 

    	 

    	 

    

 

1.
Parties 

 

1.1.
This agreement is made effective this 19th day of September, 2012 between LightPath Technologies, Inc., having offices at 2603
Challenger Tech Court Suite 100, Orlando, FL. 32826 USA (“LightPath”), and New
Hua Guang, Information Materials Co., Ltd. having offices at No. 67 ChaNHGong Beilu, Xianqfan, Hubei 441057, China (“NHG”).

 

2. Definitions

 

2.1 “Blank” means
the form of Gradium used to make individual optical elements following core drilling or cutting and prior to optical finishing.

 

2.2 “Boule” means
the form of Gradium prior to core drilling or otherwise cutting Blanks.

 

2.3 “Contract Year”
means each succeeding 12-month period commencing on the effective date of this agreement and each subsequent anniversary thereof
during the term of this agreement.

 

2.4 “Delta Z” means
the distance within a Blank, measured in millimeters, from the high index surface of a Boule to the theoretical apex of the lens.

 

2.5 “Gradium” means
Gradium Glass, a specialty optical glass developed by LightPath with a variable refractive index profile in the axial direction.

 

2.6 “NHG” means Hubei,
New Hua Guang Information Materials Co., Ltd.

 

2.7 “IP” means (a)
the patents set forth on Attachment A, (b) the trademarks set forth on Attachment B and (c) such other trade secrets, information
(confidential or otherwise), technical data, techniques, processes, methods, plans, designs, drawings, schematics, specifications,
test procedures, algorithms, technology, know-how, documentation and materials provided by LightPath to NHG related to Gradium,
including Gradium glass compositions and refractive index.

 

2.8. “LightPath”
means LightPath Technologies Inc.

 

2.9. “Prism”
means a test sample taken from a Gradium Boule used to measure refractive index profile precision.

 

2.10. “Territory”
means the continent of Asia including, specifically, the country of China.

 

    	 

    	 

    

 

3. Purpose and
Overview

 

3.1. The purpose
of this agreement is to govern the licensing of IP related to Gradium by LightPath to NHG and the manufacturing, sales and distribution
of Gradium and Gradium products.

 

3.2. Under this agreement, NHG will:

 

3.2.1.
Manufacture Gradium for NHG’s own use and manufacture Gradium and products from Gradium
for sale to third parties only in the Territory. 

 

3.2.2.
Sell Gradium to LightPath under terms set forth below for LightPath’s own use and for sale and cooperate with LightPath to
schedule production and delivery of such Gradium in accordance with LightPath’s purchase requirements.

 

3.2.3.
Not sell Gradium or materials or products from Gradium to any past, present or future LightPath customers, as identified by LightPath
to NHG from time to time, without LightPath’s written consent. 

 

3.2.4.
Conduct its business in the manufacture and sale of Gradium and Gradium products as a principal for its own account and shall pay
and assume responsibility for any and all cost, expense and risk incurred in connection with the conduct of its business. This
agreement does not in any way create the relationship of principal and agent, legal representative or any similar relationship
between LightPath and NHG. NHG has no right or authority to and shall not act or represent itself directly or by implication as
agent or legal representative for LightPath and will not incur or attempt to incur any obligation or responsibility, express or
implied, on behalf of or in the name of or to bind LightPath,
or make any representation, on behalf of or in the name of LightPath. NHG shall not sublicense any IP related to Gradium appoint
an associate manufacturer or sub-manufacturer of Gradium without the prior written consent of LightPath. 

 

3.2.5.
Use its best efforts to sell and promote the
sale of Gradium and Gradium products, which best efforts shall include but not be limited to prompt performance of all of its obligations
under this agreement.

 

3.3. Under this agreement, LightPath will:

 

3.3.1.
Grant an exclusive license to LightPath IP as described in Section 5.1 below.

 

3.3.2. Not grant the right
to produce Gradium-based products to any other third party unless this agreement expires, terminates or this license is converted
to a non-exclusive basis as set forth below.

 

3.3.3. Endeavor to obtain from
LightPath’s current licensee (Hikari) all intellectual property to which LightPath is entitled related to Gradium and to
pay the costs associated with such transfer.

 

3.3.4.
Within 10 days after NHG has produced Gradium meeting the standards set forth in Section 13, deliver to NHG LightPath’s projections
for its purchase requirements for Gradium for the remainder of calendar year 2012 and cooperate with NHG to schedule production
and delivery of such Gradium. 

 

    	 

    	 

    

 

3.3.5.
Within one week after execution of this agreement by both parties, to send drawings of the melting furnace to NHG for review and
determination by NHG whether it will accept and use the melting furnace for its production of Gradium. 

 

3.3.6. Following
LightPath’s receipt of the payment set forth in Section 10.1.1 below, provide documentation in its possession regarding the
manufacturing process for Gradium, including glass compositions and refractive index, glass melting, and, if NHG has determined
it will use the melting furnace, specifications and work instructions for the furnace and work instructions of the checkout.

 

3.3.7. Buy
Gradium from NHG under terms set forth below.

 

3.3.8. Agree
to allow NHG’s customers within the Territory only to use and sell products made from Gradium which is produced by NHG.

 

4. This section
intentionally left blank.

 

5.
License and Trademark Use 

 

5.1.
LightPath grants to NHG an exclusive, non-assignable, non-transferable license (with no right to sublicense) to use the IP within
the Territory for so long as this agreement is in effect to manufacture Gradium (i) for use by NHG for its own purposes and for
sale in the Territory only, (ii) from which NHG will manufacture products to sell to third parties in the Territory only and (iii)
to be sold by NHG to LightPath.

 

5.2. Notwithstanding
the license granted to NHG under this agreement, it is expressly agreed and acknowledged by NHG that any and all technology, information,
materials and/or intellectual property supplied and/or licensed by LightPath pursuant to this agreement shall remain the property
of LightPath and NHG shall not obtain any ownership interest therein nor shall NHG be entitled to use them other than as expressly
authorized by this agreement.

 

5.3. Nothing
in this agreement will prohibit LightPath from manufacturing products made from Gradium for its own use or for sale to third parties
and to market, distribute and sell such products to third parties anywhere in the world.

 

5.4.
LightPath reserves for itself all rights necessary for performance
of its rights as described herein. 

 

5.5.
NHG may use LightPath’s trademarks in NHG’s marketing and advertising only in connection with Gradium-based products
which meet the minimum quality requirements identified
in Section 13 below. 

 

    	 

    	 

    

 

6.
Royalties 

 

6.1.
Commencing in the fourth Contract Year, NHG will pay LightPath a royalty based on gross revenues of NHG and its affiliates from
the sale of Gradium and Gradium-based materials and products. The royalty percentage payable during the fourth Contract Year will
be 1% of the gross revenues of NHG and its affiliates from the sale of Gradium and Gradium-based materials and products. Royalty
percentages for each Contract Year after the fourth Contract Year will be agreed upon by the parties prior to the end of the year
expiration of the then current Contract Year, although the percentages are anticipated to be between 1% and 4%. If the parties
are unable to agree upon a royalty percentage for any applicable Contract Year prior to the end of the then current Contract Year,
this agreement and the license granted in this agreement will terminate at the end of the then current Contract Year.

 

6.2. Following
the end of the third Contract Year, royalty payments shall be due on the 15th day of the month following the end of
each calendar quarter during the term of this agreement for sales made during the previous calendar quarter or portion thereof
in the event of a partial calendar quarter. In the event sales in such previous calendar quarter or partial calendar quarter are
not sufficient to generate a royalty at least equal to the Minimum Quarterly Royalty (prorated for any partial calendar quarter),
the Minimum Quarterly Royalty will be due. On the date each royalty payment is due, NHG will submit to LightPath a written certification
of the gross revenues generated from the sale of Gradium and Gradium-based materials and products during the prior calendar quarter
and payment of the applicable royalty amount for such sales.

 

6.3. NHG agrees
to keep and maintain proper records which bear upon royalties payable pursuant to this agreement. LightPath shall have the right
to review, copy and conduct audits of NHG’s records to verify royalties payable hereunder.

 

7. Equipment

 

7.1.
NHG will provide its own equipment for the manufacture of Gradium and Gradium-based products, except that following LightPath’s
receipt of the payment set forth in Section 10.1.1 below, LightPath will transfer and assist NHG to set up the refractive index
test equipment owned by LightPath.

 

7.2. LightPath will take reasonable
actions to assist NHG to set up the Gradium manufacturing equipment.

 

7.3. LightPath
is willing to sell to NHG certain selected equipment used in the production of Gradium that is available and in LightPath’s
possession upon request by NHG under prices and other terms to be agreed upon by the parties.

 

7.4.
All costs, including packing, shipping, insurance and customs costs and any applicable taxes for any equipment provided by LightPath
are to be paid by NHG and NHG shall be responsible for compliance with all laws and regulations regarding the export from the United
States and import into China of all such equipment.

 

    	 

    	 

    

 

8. This section intentionally left blank.

 

9. Intellectual Property

 

9.1.
LightPath shall be solely responsible for all fees, including maintenance fees, of LightPath’s
IP licensed hereunder; provided that, in its discretion, LightPath may cease payment of such fees.

 

9.2.
Subject to LightPath’s agreement to enforce and/or defend any of its IP in any jurisdiction (other than litigation against
infringers as contemplated by Section 9.15 below), including any of its patents, NHG
and LightPath will equally share the cost of enforcing and/or defending any such IP resulting from NHG’s use of LightPath’s
IP, except that NHG will not be responsible for payment of any litigation costs arising from any of LightPath’s pending patents
in the European Patent Office. Any monies received or paid as a result of such enforcement or defense of LightPath’s
IP shall be paid to LightPath only. 

 

9.3.
Each party must notify the other in a timely manner of any suspected IP infringement. 

 

9.4.
NHG will pay all fees on any new intellectual property rights applied for by NHG.

 

9.5.
The IP license rights granted to NHG are for NHG ‘s
use only and may not be disclosed or sublicensed to any third party in any manner or form. 

 

9.6.
NHG agrees to take all necessary and appropriate steps to protect the IP and any other intellectual property rights of LightPath,
including but not limited to requiring employees, subcontractors
and customers who will have access to confidential information to sign confidentiality agreements in form and substance acceptable
to LightPath. The process of making lenses from Gradium material is not considered confidential material.

 

9.7.
Upon termination of this agreement each party will discontinue use of the other’s intellectual property rights, including
the IP, and will return all such proprietary material to
the owner of the applicable intellectual property rights and any grant by the owner of intellectual property rights of any kind
under this agreement shall terminate. 

 

9.8.
NHG recognizes and agrees that LightPath is the owner of all LightPath IP and nothing
in this agreement shall grant NHG any rights, ownership or otherwise, in said IP, except for those rights explicitly set forth
herein. NHG further recognizes that a breach of any of the obligations of this section due to either
party’s negligence will result in irreparable and continuing
damage to LightPath for which there is not adequate remedy at law, and that LightPath should be entitled to injunctive relief and/or
a decree for specific performance, reasonable attorney’s fees and such other relief as may be proper. 

 

    	 

    	 

    

 

9.9.
NHG owns any new intellectual property developed by NHG and agrees to assign a perpetual, non-exclusive
license to LightPath for all new intellectual property developed by NHG based on, derived from,
or extended from the IP or other of LightPath’s intellectual property. 

 

9.10.
LightPath will pay NHG a royalty equal to the royalty negotiated for Contract Year 4 and beyond
for all products manufactured and sold by LightPath using NHG intellectual property. 

 

9.11.
LightPath agrees to take all necessary and appropriate
steps to protect NHG’s intellectual property including but not limited to
requiring employees, subcontractors and customers who will have access to confidential information to sign confidentiality agreements.

 

9.12.
NHG agrees to immediately notify LightPath in writing
of all new intellectual property developed by NHG described in Section 9.9. In no event shall such written notification be provided
later than 30 days after developing new intellectual property.

 

9.13.
LightPath recognizes and agrees that NHG is the owner of all NHG intellectual property, and that a breach of any of the obligations
of this section due to either party’s negligence
will result in irreparable and continuing damage to NHG for which there is not adequate remedy
at law, and that NHG should be entitled to injunctive relief and/or a decree for specific performance,
reasonable attorney’s
fees and such other relief as may be proper.

 

9.14.
This agreement does not give
NHG ownership in any LightPath IP; only the right to manufacture and , use,
and sell Gradium-based products under the license granted
in this agreement while this agreement is in effect. 

 

9.15.
In matters other than those contemplated by Section 9.2 above, concerning infringement by third parties making,
using or selling infringing products corresponding to any of LightPath’s IP or other intellectual property rights related
to Gradium: 

 

9.15.1.
NHG is empowered to bring suit
in its own name or,
if required by law, jointly
with LightPath, at its own expense and on its own behalf
for infringement of LightPath’s IP; 

 

9.15.2.
NHG will inform LightPath immediately upon NHG becoming aware of any infringement of the IP or any of LightPath’s other intellectual
property related to Gradium. NHG will correspond with known
infringers and to promptly provide notice them of infringement
and a direction to cease such infringement, and will promptly advise LightPath of NHG’s notification to such infringers.

 

9.15.3.
NHG will provide copies of all correspondences to and from infringers. 

 

9.15.4.
NHG is entitled to,
in any such suit brought by it to
enjoin infringement and for which it bears all of the costs, to collect for
its use, damages, profits, and awards of whatever nature
recoverable for such infringement, except that any sums awarded
to NHG shall be considered revenues for which LightPath will be entitled to royalties.

 

    	 

    	 

    

 

9.15.5.
At the option of LightPath, LightPath may at its expense, sue infringers. LightPath will retain
all damages received in patent litigation it conducts. Where LightPath
has agreed to and has taken over
responsibility for litigation initiated by NHG, the parties
will retain damages in the same proportion that they have
contributed to the cost of the litigation. 

 

10.
Pricing and Payment Schedule 

 

10.1.
The total cost to NHG
of the license granted under this agreement is the royalties
payable under Section 6 above and the sum of USD $150,000
which shall be payable as follows:

 

10.1.1.
$50,000 shall be paid within ten days after the effective date of this agreement.

 

10.1.2. $60,000
shall be paid upon LightPath’s approval and acceptance of a 9 inch Boule and a 13 inch Boule meeting the standards set forth
in this agreement.

 

10.1.3. $40,000
shall be paid upon promptly upon achievement of six months of Gradium production.

 

10.2.
NHG agrees to sell Gradium and Gradium-based materials and products to LightPath at a price equal to or less than ten percent (10%)
below the lowest selling price charged by NHG to any customer of NHG purchasing Gradium or the same or similar Gradium-based materials
or products; provided, that the cost to LightPath per Boules shall not exceed USD$300 for a nine inch Boule or USD$650 for a thirteen
inch Boule unless otherwise mutually agreed.

 

10.3.
NHG shall pay all license fees, sales, use, service use, occupation, retailer’s occupation,
service occupation, personal property, transaction and excise taxes and any other fees, assessments or taxes which may be assessed
or levied by any national, state or local government and any departments and subdivisions thereof, against any Gradium manufactured
or sold by NHG, or any Gradium under NHG’s direct or indirect control.

 

11. This section
intentionally left blank.

 

12. Term

 

12.1. The initial
term of this agreement is five years from the effective date of this agreement unless earlier terminated in accordance with this
agreement or as otherwise mutually agreed upon in writing.

 

    	 

    	 

    

 

12.2.
Upon completion of the initial five year term, this agreement shall automatically renew for successive one year periods unless:

 

12.2.1.
Termination is mutually agreed in writing at which time termination shall be immediate. 

 

12.2.2.
Either party notifies the other in writing at least six months prior to the end of the then current Contract Year that such party
will not renew the agreement. 

 

12.3.
This agreement shall terminate automatically and without the giving of notice in the event that NHG shall become insolvent, or
shall ask its creditors for a moratorium, or shall file or have filed against it a petition in bankruptcy, or shall suffer appointment
of a temporary or permanent receiver, trustee, or custodian for all or a substantial part of its assets who shall not be discharged
within thirty (30) days. 

 

12.4.
Notwithstanding any other provision of this Section 12, either party may terminate this agreement for a material breach by the
other party of any of its obligations under this agreement by notifying the other party of such default and allowing the other
party thirty (30) days within which to cure such default. If
such default is not cured within thirty (30) days, the party who gave such notice of default may terminate this agreement at any
time thereafter upon notice to the other party. If the default is quality based and NHG is actively working to correct the problems,
the time period will be extended to 60 days. If the default is cured within such time period but thereafter repeated, the party
who gave such notice of default may terminate this agreement without any further opportunity to cure immediately upon giving the
defaulting party notice of such termination. 

 

12.5.
The provisions of Sections 9.5, 9.6, 9.7, 9.8, 9.9,
10, 16 and 17.1 shall survive the termination or expiration
of this agreement and shall be liberally construed in favor of LightPath.

 

13. Quality Requirements

 

13.1.
It is LightPath’s desire to always receive the highest quality possible in Gradium Boules
purchased from NHG. 

 

13.2.
Minimum wavefront quality levels for Gradium Glass are defined by LightPath Procurement Specifications
as listed in paragraph 13.4. 

 

13.3.
The minimum dimension for a 9 inch boule across the short section is 7 inches and 8 inches for all other dimensions. The minimum
dimension for a 13 inch Boule across the short section is 11 inches and 12 inches for all other dimensions. All Boules are to be
milled to standard thickness per LightPath procedures unless otherwise mutually agreed. 

 

13.4.
The quality requirements are defined in the LightPath Procurement Specifications for the various
types of Gradium Boules; specifications, 9000179Rev A, 9000180RevA, 9000181Rev A, 9000182Rev A and 9000183Rev A. 

 

    	 

    	 

    

 

13.5. The
wavefront quality and profile precision is to be measured by NHG for every Boule to be sold to LightPath and the data from both
prisms is to be provided with each Boule.

 

13.6. The profile
precision is to be measured using at least 2 prisms spaced a maximum distance apart from one another.

 

13.7. When purchasing
Boules for large lens orders, LightPath may request that NHG mill all Boules for that order to a common Delta Z value.

 

13.8. For all
products sold and/or manufactured directly or indirectly by NHG under this agreement, NHG shall certify to LightPath in writing
whether such products meet or fail the quality provisions set forth herein.

 

14.
Training 

 

14.1.
Upon execution of this agreement, LightPath will train NHG in the production and testing of Gradium and in lens fitting techniques
to accurately define Delta Z for any given lens using measured profile data. 

 

15. Non Performance and Rights of
Manufacture

 

15.1.
If at any time, and in its sole discretion, LightPath deems that NHG is not able or willing to provide Gradium glass of appropriate
quality or quantity or in a timely manner, LightPath reserves the right, among any other rights LightPath may have, to manufacture
Gradium glass for its own use and for sale. LightPath may
also terminate this agreement immediately if NHG does not remedy quality failures within 30 days after being notified by LightPath
of its intent to terminate for quality failure reasons unless otherwise agreed in writing.

 

16. General
Provisions

 

16.1.
This is the entire agreement between NHG and LightPath regarding the matters set forth herein. Neither party can change any part
of the agreement without the prior written consent of the other party, nor may this agreement be amended except in writing signed
by both parties. This agreement and all matters arising from or related to it or its subject
matters shall be governed by, remedied and construed in accordance with the laws of the State of Florida, USA, without resort or
regard to Florida’s conflict of laws principles or precedent. The parties hereby agree to be bound by the exclusive jurisdiction
of any federal or state court located in Orange County, Florida and shall not challenge the proprietary of venue thereof, including
but not limited to assertion of a challenge based on in convenience, except that, at LightPath’s option, the parties shall
submit any controversy or dispute under this agreement to binding arbitration before an independent
and mutually agreed board of arbitrators, which arbitration will be conducted in Orlando, Florida under the rules and regulations
of the American Arbitration Association. If a suit is filed or any matter is submitted to arbitration hereunder,
the prevailing party in such suit or arbitration is entitled to recover from the non-prevailing
party its reasonable attorney’s fees and costs. Each
party will notify the other as soon as reasonably practicable after determining that the other party is in breach of any obligation
under or provision of this agreement, but if either party delays in notifying the other, the non-defaulting party will still retain
all rights and remedies available to it under this agreement. 

 

    	 

    	 

    

 

16.2.
This agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns.
NHG shall not have the right to assign or otherwise transfer its rights hereunder or any interest herein without the prior written
consent of LightPath. 

 

16.3.
Neither LightPath nor NHG shall by reason of the termination or non-renewal of this agreement
be liable to the other for compensation, reimbursement or damages on account of the loss of prospective profits, or anticipated
sales or on account of expenditures, investments, leases,
property improvements or commitments in connection with the business or good will of LightPath, NHG, or otherwise. 

 

16.4.
All notices, demands and other communications to be given or delivered under or by reason of the provisions of this agreement shall
be in writing and shall be deemed to have been given and received when personally delivered or as of ten (10) business days following
the date of deposit thereof for mailing if mailed by certified mail, return receipt requested, three (3) business day after deposit
with a recognized overnight carrier service or upon electronic or other confirmation of successful transmission of a facsimile.
Notices, demands and communications to the parties hereto, unless another address is specified in writing in accordance herewith,
shall be sent to the parties’ respective addresses set forth on the signature page to this agreement.

 

16.5.
If any term or provision of this agreement or the application thereof to any person or circumstance
shall, to any extent, be invalid or unenforceable, then, without waiving any right of appeal: (a) if possible, the provision shall
be reconstituted to approximate as closely as legally possible to achieve the intent evident in the term or provision; and (b)
the remainder of this agreement or the application of such term or provision to persons or circumstances other than those as to
which it is held invalid and unenforceable, shall not be affected thereby. In any case, each term and provision of this agreement
shall be valid and be enforceable to the fullest extent permitted by law. 

 

16.6.
This agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed to be
an original and all of which taken together shall constitute but one and the same instrument.
Headings in this agreement are included
herein for convenience of reference only and shall not constitute a part of this agreement for any other purpose. 

 

16.7.
If either party to this agreement shall breach its representations or warranties set forth herein or shall fail to fulfill or perform
any of its covenants or obligations in this agreement, that party shall pay all costs, including, without limitation, reasonable
attorneys’ fees, that may be incurred by the other to enforce such other party’s rights hereunder.
Notwithstanding anything in this agreement to the contrary, the covenants contained in this
Section shall survive any termination of this agreement. 

 

    	 

    	 

    

 

16.8.
Each party agrees that during the course of this agreement, information that is confidential or proprietary may be disclosed to
the other party, including, but not limited to software, technical processes and formulas, source codes, product designs, sales,
cost and other unpublished financial information, product and business plans, advertising revenues, usage rates, advertising relationships,
projections, and marketing data (“Confidential Information”). Confidential Information shall not include information
that the receiving party can demonstrate (a) is, as of the time of its disclosure, or thereafter becomes part of the public domain
through a source other than the receiving party or any other party subject to a confidentiality obligation regarding such information,
(b) was known to the receiving party as of the time of its disclosure,
as proven through written business records, from a source not bound by a confidentiality obligation regarding such information,
(c) is independently developed by the receiving party without use of or reference to any Confidential Information of the other
party, as proven through written business records, or (d) is subsequently learned from a third party not under a confidentiality
obligation to the providing party. Except as provided for
in this agreement, each party shall not make any disclosure of the other party’s Confidential Information to anyone other
than its employees who have a need to know in connection with this agreement and have executed and delivered to the other party
a confidentiality agreement in form and substance acceptable to the other party. Each
party shall notify its employees of their confidentiality obligations with respect to the Confidential Information and shall require
its employees to comply with these obligations. The confidentiality
obligations of each party and its employees shall survive
the expiration or termination of this agreement for a period of three years.

 

16.9.
At any time while this agreement is in effect, NHG and LightPath may begin the negotiation process for NHG to purchase all Gradium
IP from LightPath, including its customer list. 

 

16.10. All payments
due to LightPath under this agreement shall be made in United States dollars.

 

17. Indemnity

 

17.1.
NHG agrees to defend, indemnify, and hold LightPath, and its officers, directors, agents, employees,
successors and assigns, and each of them, harmless from and against
any and all injury, claim, loss, damage, costs, expenses, actions and suits, whether groundless or otherwise, and
from and against any and all liabilities, judgments, losses, damages, costs, charges, reasonable attorneys’ fees and other
expenses of every nature and character attributable, directly or indirectly, to NHG’s
acts or omissions in the operation of its business including, but not limited to, its operation under the license granted in this
agreement; its use of the IP or other intellectual property, including any use that infringes on or violates any third party’s
intellectual property rights or applicable law or regulation; its manufacture, marketing, sale and distribution of Gradium or Gradium
based products, including the export or import of Gradium and Gradium based products; its purchase, export, transport, import,
use or possession of any equipment acquired from LightPath; or its performance of its obligations or breach of its covenants,
representations or warranties contained in this agreement. 

 

    	 

    	 

    

 

17.2.
LightPath agrees to defend, indemnify, and hold NHG,
and its officers, directors, agents, employees, successors and
assigns, and each of them, harmless from and against any and all injury, claim, loss, damage,
costs, expenses, actions and suits, whether groundless or otherwise, and from and against any
and all liabilities, judgments, losses, damages, costs, charges, reasonable attorneys’
fees and other expenses of every nature and character attributable, directly or indirectly, to LightPath’s breach of its
covenants, representations or warranties contained in this agreement. 

 

18. Attachments

 

The following Attachments are hereby attached
and incorporated into this agreement:

 

Attachment A
entitled “LightPath U.S., PCT and Foreign Patent Summary Report”; and

 

Attachment B
entitled “LightPath U.S. Trademark Summary.”

 

[Signatures
on Following Page]

 

    	 

    	 

    

 

IN WITNESS WHEREOF, the parties hereto have
executed this Memorandum of Understanding as of the day and year first written above.

 

	 	“LIGHTPATH”
	 	 
	 	LightPath Technologies Inc.

 

	 	By:	/s/ James Gaynor
	 	 	James Gaynor, Chief Executive Officer

 

	 	Address:	2603 Challenger Tech Court
	 	 	Suite 100
	 	 	Orlando, Florida 32826
	 	 	USA
	 	 	Attention:  James Gaynor
	 	Fax:	407-382-4007

 

	 	“NHG”
	 	 
	 	Hubei New Hua Guang Information Materials Co., Ltd.

 

	 	By:	/s/ Zhang Wei
	 	Name:	Zhang Wei
	 	Title:	Standing Deputy General Manager

 

	 	Address:	No. 67 ChaNHGong Beilu
	 	 	Xianqfan, Hubei 441057
	 	 	China
	 	 	Attention: Zhang Wei
	 	Fax:	0086-710-3349308SECURITIES PURCHASE AGREEMENT

 

THIS SECURITIES PURCHASE
AGREEMENT (this “Agreement”) is made as of October 10, 2012 by and between Crumbs Bake Shop, Inc., a Delaware
corporation (the “Company”), and each of the Investors set forth on the signature pages affixed hereto (each
an “Investor” and collectively the “Investors”).

 

Recitals

 

A.The Company and
each of the Investors are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded
by the provisions of Regulation D (“Regulation D”), as promulgated by the U.S. Securities and Exchange Commission
(the “SEC”) under the Securities Act of 1933, as amended;

 

B.The Investors
wish to purchase from the Company, and the Company wishes to sell and issue to the Investors, upon the terms and conditions stated
in this Agreement, an aggregate of 4,456,968 shares (the “Shares”) of the Company’s common stock, par
value $0.0001 per share (together with any securities into which such common stock may be reclassified, whether by merger, charter
amendment or otherwise, the “Common Stock”), at a purchase price of $2.21 per Share;

 

C.Contemporaneous
with the sale of the Shares, the parties hereto will execute and deliver a Registration Rights Agreement, in the form attached
hereto as Exhibit A (the “Registration Rights Agreement”), pursuant to which the Company will agree to
provide certain registration rights under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder,
and applicable state securities laws; and

 

D.Prior to the
date hereof, 1,560,000 Class B Exchangeable Units of Crumbs Holdings, LLC, together with 156,000 shares of the Company’s
Series A Voting Preferred Stock, par value $0.0001 per share, have been irrevocably exchanged for an aggregate of 1,560,000 shares
of Common Stock (the “Restructuring”).

 

In consideration of
the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto agree as follows:

 

Agreement

 

1.                 
Definitions. In addition to those terms defined above and elsewhere in this Agreement, for the purposes of
this Agreement, the following terms shall have the meanings set forth below:

 

“Affiliate”
means, with respect to any Person, any other Person which directly or indirectly through one or more intermediaries Controls, is
controlled by, or is under common Control with, such Person.

 

    	 

    	 

    
 

“Agents”
means Janney Montgomery Scott, LLC and Susman Partners, LLC d/b/a Threadstone Partners.

 

“Business
Day” means a day, other than a Saturday or Sunday, on which banks in New York City are open for the general transaction
of business.

 

“Common Stock
Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including without limitation, any debt, preferred stock, rights, options, warrants or other instrument
that is at any time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

 

“Company’s
Knowledge” means the actual knowledge of the executive officers (as defined in Rule 405 under the 1933 Act) of the Company,
after due inquiry.

 

“Confidential
Information” means trade secrets, confidential information and know-how (including but not limited to ideas, formulae,
compositions, processes, procedures and techniques, research and development information, computer program code, performance specifications,
support documentation, drawings, specifications, designs, business and marketing plans, and customer and supplier lists and related
information).

 

“Control”
(including the terms “controlling”, “controlled by” or “under common control with”)
means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person,
whether through the ownership of voting securities, by contract or otherwise.

 

“Effective
Date” means the date on which the initial Registration Statement is declared effective by the SEC.

 

“Effectiveness
Deadline” means the date on which the initial Registration Statement is required to be declared effective by the SEC
under the terms of the Registration Rights Agreement.

 

“Intellectual
Property” means all of the following: (i) patents, patent applications, patent disclosures and inventions (whether or
not patentable and whether or not reduced to practice); (ii) trademarks, service marks, trade dress, trade names, corporate names,
logos, slogans and Internet domain names, together with all goodwill associated with each of the foregoing; (iii) copyrights and
copyrightable works; (iv) registrations, applications and renewals for any of the foregoing; and (v) proprietary computer software
(including but not limited to data, data bases and documentation).

 

“Material
Adverse Effect” means a material adverse effect on (i) the assets, liabilities, results of operations, condition (financial
or otherwise), business, or prospects of the Company and its Subsidiaries taken as a whole, or (ii) the ability of the Company
to perform its obligations under the Transaction Documents.

    	-2-

    	 

    
 

“Material
Contract” means any contract, instrument or other agreement to which the Company or any Subsidiary is a party or by which
it is bound which is material to the business of the Company and its Subsidiaries, taken as a whole, including those that have
been filed or were required to have been filed as an exhibit to the SEC Filings pursuant to Item 601(b)(4) or Item 601(b)(10) of
Regulation S-K.

 

“Nasdaq”
means The NASDAQ Capital Market.

 

“Person”
means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company,
joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically
listed herein.

 

“Purchase
Price” means Two Dollars and Twenty-One Cents ($2.21).

 

“Registration
Statement” has the meaning set forth in the Registration Rights Agreement.

 

“Required
Investors” means (i) prior to the Closing, (A) any Investor which, together with its Affiliates, has agreed to purchase
at least 1,000,000 Shares pursuant to this Agreement and (B) the Investors agreeing to purchase a majority of the Shares pursuant
to this Agreement, and (ii) from and after the Closing, (A) any Investor which, together with its Affiliates, beneficially owns
at least 1,000,000 Shares and (B) the Investors beneficially owning a majority of the Shares then beneficially owned by all Investors.

 

“SEC Filings”
has the meaning set forth in Section 4.6.

 

“Subsidiary”
of any Person means another Person, an amount of the voting securities, other voting ownership or voting partnership interests
of which is sufficient to elect at least a majority of its Board of Directors or other governing body (or, if there are no such
voting interests, 50% or more of the equity interests of which) is owned directly or indirectly by such first Person.

 

“Transaction
Documents” means this Agreement and the Registration Rights Agreement.

 

“1933 Act”
means the Securities Act of 1933, as amended, or any successor statute, and the rules and regulations promulgated thereunder.

 

“1934 Act”
means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations promulgated thereunder.

 

2.                 
Purchase and Sale of the Shares. Subject to the terms and conditions of this Agreement, on the Closing Date,
each of the Investors shall severally, and not jointly, purchase, and the Company shall sell and issue to the Investors, the Shares
in the respective amounts set forth opposite the Investors’ names on the signature pages attached hereto in exchange for
the Purchase Price as specified in Section 3 below.

    	-3-

    	 

    
 

3.                 
Closing. Unless other arrangements have been made with a particular Investor, upon confirmation that the other
conditions to closing specified herein have been satisfied or duly waived by the Investors, the Company shall deliver to Lowenstein
Sandler PC, in trust, a certificate or certificates, registered in such name or names as the Investors may designate, representing
the Shares, with instructions that such certificates are to be held for release to the Investors only upon payment in full of the
Purchase Price to the Company by all the Investors. Unless other arrangements have been made with a particular Investor, upon such
receipt by Lowenstein Sandler PC of the certificates, each Investor shall promptly, but no later than one Business Day thereafter,
cause a wire transfer in same day funds to be sent to the account of the Company as instructed in writing by the Company, in an
amount representing such Investor’s pro rata portion of the Purchase Price as set forth on the signature pages to this Agreement.
On the date (the “Closing Date”) the Company receives the Purchase Price, the certificates evidencing the Shares
shall be released to the Investors (the “Closing”). The Closing of the purchase and sale of the Shares shall
take place at the offices of Lowenstein Sandler PC, 1251 Avenue of the Americas, 18th Floor, New York, New York 10020, or at such
other location and on such other date as the Company and the Investors shall mutually agree.

 

4.                 
Representations and Warranties of the Company. The Company hereby represents and warrants to the Investors
that, except as set forth in the schedules delivered herewith (collectively, the “Disclosure Schedules”):

 

4.1             
Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing
and in good standing under the laws of the State of Delaware, and each of the Company’s Subsidiaries is an entity duly formed,
validly existing and in good standing under the laws of the jurisdiction under which it was formed. The Company has all requisite
power and authority to carry on its business as now conducted and to own or lease its properties and to execute, deliver and perform
all of its obligations under the Transaction Documents and to consummate the transactions contemplated thereby. Each of the Company’s
Subsidiaries has all requisite power and authority to carry on its business as now conducted and to own or lease its properties.
Each of the Company and its Subsidiaries is qualified to do business as a foreign entity and is in good standing in each jurisdiction
in which the conduct of its business or its ownership or leasing of property makes such qualification or leasing necessary unless
the failure to be so qualified has not had and could not reasonably be expected to have a Material Adverse Effect. The Company’s
Subsidiaries are listed on Schedule 4.1 hereto.

 

4.2             
Authorization. The Company has full power and authority and has taken all requisite action on the part of
the Company, its officers, directors and stockholders necessary for (i) the authorization, execution and delivery of the Transaction
Documents, (ii) the authorization of the performance of all obligations of the Company hereunder or thereunder, (iii) the authorization,
issuance (or reservation for issuance) and delivery of the Shares and (iv) the Restructuring Assuming the due execution and delivery
by the counterparties thereto, the Transaction Documents constitute the legal, valid and binding obligations of the Company, enforceable
against the Company in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium
and similar laws of general applicability, relating to or affecting creditors’ rights generally and to general equitable
principles.

    	-4-

    	 

    
 

4.3             
Capitalization. Schedule 4.3 sets forth as of the date hereof and after giving effect to the Restructuring
(a) the authorized capital stock of the Company; (b) the number of shares of capital stock issued and outstanding; (c) the number
of shares of capital stock issuable pursuant to the Company’s stock plans as in effect on the date hereof (“Stock
Plans”); and (d) the number of shares of capital stock issuable and reserved for issuance pursuant to securities exercisable
for, or convertible into or exchangeable for any shares of capital stock of the Company. All of the issued and outstanding shares
of the Company’s capital stock have been duly authorized and validly issued and are fully paid, nonassessable and free of
pre-emptive rights and were issued in full compliance with applicable state and federal securities law and any rights of third
parties. Except as described on Schedule 4.3, all of the issued and outstanding capital securities of each Subsidiary have
been duly authorized and validly issued and are fully paid, nonassessable and free of pre-emptive rights, were issued in full compliance
with applicable state and federal securities law and any rights of third parties and are owned by the Company, beneficially and
of record, subject to no lien, encumbrance or other adverse claim. Except as described on Schedule 4.3, no Person is entitled
to pre-emptive or similar statutory or contractual rights with respect to any securities of the Company. Except as described on
Schedule 4.3, there are no outstanding warrants, options, convertible securities or other rights, agreements or arrangements
of any character under which the Company or any of its Subsidiaries is or may be obligated to issue any equity securities of any
kind and, except as contemplated by this Agreement, neither the Company nor any of its Subsidiaries is currently in negotiations
for the issuance of any equity securities of any kind. Except as described on Schedule 4.3 and except for the Registration
Rights Agreement, there are no voting agreements, buy-sell agreements, option or right of first purchase agreements or other agreements
of any kind among the Company and any of the securityholders of the Company relating to the securities of the Company held by them.
Except as described on Schedule 4.3 and except as provided in the Registration Rights Agreement, no Person has the right
to require the Company to register any securities of the Company under the 1933 Act, whether on a demand basis or in connection
with the registration of securities of the Company for its own account or for the account of any other Person.

 

Except as described
on Schedule 4.3, the issuance and sale of the Shares hereunder will not obligate the Company to issue shares of Common Stock
or other securities to any other Person (other than the Investors) and will not result in the adjustment of the exercise, conversion,
exchange or reset price of any outstanding security.

 

Except as described
on Schedule 4.3, the Company does not have outstanding stockholder purchase rights or “poison pill” or
any similar arrangement in effect giving any Person the right to purchase any equity interest in the Company upon the occurrence
of certain events.

 

4.4             
Valid Issuance. The Shares have been duly and validly authorized and, when issued and paid for pursuant to
this Agreement, will be validly issued, fully paid and nonassessable, and shall be free and clear of all encumbrances and restrictions
(other than those created by the Investors), except for restrictions on transfer set forth in the Transaction Documents or imposed
by applicable securities laws.

    	-5-

    	 

    
 

4.5             
Consents. The (i) execution, delivery and performance by the Company
of the Transaction Documents, (ii) the offer, issuance and sale of the Shares and (iii) the Restructuring require no consent of,
action by or in respect of, or filing with, any Person, governmental body, agency, or official other than (A) filings that have
been made pursuant to applicable state securities laws or the rules of any applicable securities exchange or securities market,
(B) post-sale filings pursuant to applicable state and federal securities laws and the rules of any applicable securities exchange
or securities market which the Company undertakes to file within the applicable time periods, and (C) such consents, actions and
filings as have been made and are in full force and effect. Subject to the accuracy of the representations and warranties of each
Investor set forth in Section 5 hereof, the Company has taken all action necessary to exempt (i) the issuance and sale of the Shares
and (ii) the other transactions contemplated by the Transaction Documents from the provisions of any stockholder rights plan or
other “poison pill” arrangement, any anti-takeover, business combination or control share law or statute binding
on the Company or to which the Company or any of its assets and properties may be subject and any provision of the Company’s
Certificate of Incorporation or Bylaws that is or could reasonably be expected to become applicable to the Investors as a result
of the transactions contemplated hereby, including without limitation, the issuance of the Shares and the ownership, disposition
or voting of the Shares by the Investors or the exercise of any right granted to the Investors pursuant to this Agreement or the
Registration Rights Agreement.

 

4.6             
Delivery of SEC Filings; Business. The Company has made available to the Investors through the EDGAR system,
true and complete copies of the Company’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2011
(the “10-K”), and all other reports filed by the Company pursuant to the 1934 Act since the filing of the 10-K
and prior to the date hereof (collectively, the “SEC Filings”). The SEC Filings are the only filings required
of the Company pursuant to the 1934 Act for such period. The Company and its Subsidiaries are engaged in all material respects
only in the business described in the SEC Filings and the SEC Filings contain a complete and accurate description in all material
respects of the business of the Company and its Subsidiaries, taken as a whole.

 

4.7             
Use of Proceeds. The net proceeds of the sale of the Shares hereunder shall be used by the Company for working
capital and general corporate purposes.

 

4.8             
No Material Adverse Change. Since December 31, 2011, except (A) as identified and described in the SEC Filings,
(B) for the transactions constituting the Restructuring, or (C) as described on Schedule 4.8, there has not been:

 

(a)               
any change in the consolidated assets, liabilities, financial condition or operating results of the Company from
that reflected in the financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended
June 30, 2012 (as amended by Amendment No. 1 on Form 10-Q/A filed with the SEC on August 17, 2012), except for changes in the ordinary
course of business which have not had and could not reasonably be expected to have a Material Adverse Effect, individually or in
the aggregate;

    	-6-

    	 

    
 

(b)              
any declaration or payment of any dividend, or any authorization or payment of any distribution, on any of the capital
stock of the Company, or any redemption or repurchase of any securities of the Company;

 

(c)               
any material damage, destruction or loss, whether or not covered by insurance to any assets or properties of the
Company or its Subsidiaries;

 

(d)              
any waiver, not in the ordinary course of business, by the Company or any Subsidiary of a material right or of a
material debt owed to it;

 

(e)               
any satisfaction or discharge of any lien, claim or encumbrance or payment of any obligation by the Company or a
Subsidiary, except in the ordinary course of business and which have not had and could not reasonably be expected to have a Material
Adverse Effect taken as a whole (as such business is presently conducted and as it is proposed to be conducted);

 

(f)               
any change or amendment to the Company’s Certificate of Incorporation or Bylaws, or material change to any
Material Contract;

 

(g)              
any material labor difficulties or labor union organizing activities with respect to employees of the Company or
any Subsidiary;

 

(h)              
any material transaction entered into by the Company or a Subsidiary other than in the ordinary course of business;

 

(i)                
any loss of the services of any key employee, or material change in the composition or duties of the senior management
of the Company or any Subsidiary;

 

(j)                
any loss or threatened loss of any customer which has had or could reasonably be expected to have a Material Adverse
Effect; or

 

(k)              
any other event or condition of any character that has had or could reasonably be expected to have a Material Adverse
Effect.

 

4.9             
SEC Filings; S-3 Eligibility.

 

(a)   
At the time of filing thereof, the SEC Filings complied as to form in all material respects with the requirements
of the 1934 Act and did not contain any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary in order to make the statements made therein, in the light of the circumstances under which they were made,
not misleading.

    	-7-

    	 

    
 

(b)   
Each registration statement and any amendment thereto filed by the Company since January 1, 2009 pursuant to the
1933 Act and the rules and regulations thereunder, as of the date such statement or amendment became effective, complied as to
form in all material respects with the 1933 Act and did not contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary in order to make the statements made therein not misleading; and each
prospectus filed pursuant to Rule 424(b) under the 1933 Act, as of its issue date and as of the closing of any sale of securities
pursuant thereto did not contain any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary in order to make the statements made therein, in the light of the circumstances under which they were made,
not misleading.

 

(c)   
The Company is eligible to use Form S-3 to register the Registrable Securities (as such term is defined in the Registration
Rights Agreement) for sale or other disposition by the Investors as contemplated by the Registration Rights Agreement.

 

4.10         
No Conflict, Breach, Violation or Default. The execution, delivery and performance of the Transaction Documents
by the Company and the issuance and sale of the Shares will not (a) conflict with or result in a breach or violation of (i) any
of the terms and provisions of, or constitute a default under, the Company’s Certificate of Incorporation or the Company’s
Bylaws, both as in effect on the date hereof (true and complete copies of which have been made available to the Investors through
the EDGAR system), or (ii) any statute, rule, regulation or order of any governmental agency or body or any court, domestic or
foreign, having jurisdiction over the Company, any Subsidiary or any of their respective assets or properties, or (b) conflict
with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the
creation of any lien, encumbrance or other adverse claim upon any of the properties or assets of the Company or any Subsidiary
or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or
both) of, any Material Contract.

 

4.11         
Tax Matters. The Company and each Subsidiary has timely prepared and filed all tax returns required to have
been filed by the Company or such Subsidiary with all appropriate governmental agencies and timely paid all taxes shown thereon
or otherwise owed by it, except for taxes which it reasonably disputes in good faith and for which appropriate reserves have been
established on the Company’s books and records The charges, accruals and reserves on the books of the Company in respect
of taxes for all fiscal periods are adequate in all material respects, and there are no material unpaid assessments against the
Company or any Subsidiary nor, to the Company’s Knowledge, any basis for the assessment of any additional taxes, penalties
or interest for any fiscal period or audits by any federal, state or local taxing authority except for any assessment which has
not had and could not reasonably be expected to have a Material Adverse Effect taken as a whole. All taxes and other assessments
and levies that the Company or any Subsidiary is required to withhold or to collect for payment have been duly withheld and collected
and paid to the proper governmental entity or third party when due. There are no tax liens or claims pending or, to the Company’s
Knowledge, threatened against the Company or any Subsidiary or any of their respective assets or properties. Except as described
on Schedule 4.11, there are no outstanding tax sharing agreements or other such arrangements between the Company and any
Subsidiary or other corporation or entity.

    	-8-

    	 

    
 

4.12         
Title to Properties. Except as disclosed in the SEC Filings, (a) the Company and each Subsidiary has good
and marketable title to all real properties and all other properties and assets owned by it, in each case free from liens, encumbrances
and defects that would materially affect the value thereof or materially interfere with the use made or currently planned to be
made thereof by them, and (b) the Company and each Subsidiary holds any leased real or personal property under valid and enforceable
leases with no exceptions that would materially interfere with the use made or currently planned to be made thereof by them.

 

4.13         
Certificates, Authorities and Permits. The Company and each Subsidiary possess adequate certificates, authorities
or permits issued by appropriate governmental agencies or bodies necessary to conduct their respective businesses now operated
by them, and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification
of any such certificate, authority or permit that, if determined adversely to the Company or such Subsidiary, could reasonably
be expected to have a Material Adverse Effect, individually or in the aggregate.

 

4.14         
Labor Matters.

 

(a)   
Except as disclosed in the SEC Filings, the Company is not a party to or bound
by any collective bargaining agreements or other agreements with labor organizations. The Company has not violated in any material
respect any laws, regulations, orders or contract terms, affecting the collective bargaining rights of employees, labor organizations
or any laws, regulations or orders affecting employment discrimination, equal opportunity employment, or employees’ health,
safety, welfare, wages and hours.

 

(b)   
(i) There are no labor disputes existing, or to the Company’s Knowledge,
threatened, involving strikes, slow-downs, work stoppages, job actions, disputes, lockouts or any other disruptions of or by the
Company’s employees, (ii) there are no unfair labor practices or petitions for election pending or, to the Company’s
Knowledge, threatened before the National Labor Relations Board or any other federal, state or local labor commission relating
to the Company’s employees, (iii) no demand for recognition or certification heretofore made by any labor organization or
group of employees is pending with respect to the Company and (iv) to the Company’s Knowledge, the Company enjoys good labor
and employee relations with its employees and labor organizations.

 

(c)   
The Company is, and at all times has been, in compliance in all material respects
with all applicable laws respecting employment (including laws relating to classification of employees and independent contractors)
and employment practices, terms and conditions of employment, wages and hours, and immigration and naturalization. There are no
claims pending against the Company before the Equal Employment Opportunity Commission or any other administrative body or in any
court asserting any violation of Title VII of the Civil Rights Act of 1964, the Age Discrimination Act of 1967, 42 U.S.C. §§
1981 or 1983 or any other federal, state or local Law, statute or ordinance barring discrimination in employment.

    	-9-

    	 

    
 

(d)   
Except as disclosed in the SEC Filings, the Company is not a party to, or bound
by, any employment or other contract or agreement that contains any severance, termination pay or change of control liability or
obligation, including, without limitation, any “excess parachute payment,” as defined in Section 280G(b) of
the Internal Revenue Code.

 

(e)   
To the Company’s Knowledge, each of the Company’s employees is a Person
who is either a United States citizen or a permanent resident entitled to work in the United States. To the Company’s Knowledge,
the Company has no liability for the improper classification by the Company of such employees as independent contractors or leased
employees prior to the Closing.

 

4.15         
Intellectual Property.

 

(a)   
All Intellectual Property of the Company and its Subsidiaries is currently in compliance in all material respects
with all legal requirements (including timely filings, proofs and payments of fees) and is valid and enforceable. No Intellectual
Property of the Company or its Subsidiaries which is necessary for the conduct of Company’s and each of its Subsidiaries’
respective businesses as currently conducted or as currently proposed to be conducted has been or is now involved in any cancellation,
dispute or litigation, and, to the Company’s Knowledge, no such action is threatened. No patent of the Company or its Subsidiaries
has been or is now involved in any interference, reissue, re-examination or opposition proceeding.

 

(b)   
All of the licenses and sublicenses and consent, royalty or other agreements concerning Intellectual Property which
are necessary for the conduct of the Company’s and each of its Subsidiaries’ respective businesses as currently conducted
or as currently proposed to be conducted to which the Company or any Subsidiary is a party or by which any of their assets are
bound (other than  generally commercially available, non-custom, off-the-shelf software application programs having a retail
acquisition price of less than $10,000 per license) (collectively, “License Agreements”) are valid and binding
obligations of the Company or its Subsidiaries that are parties thereto and, to the Company’s Knowledge, the other parties
thereto, enforceable in accordance with their terms, except to the extent that enforcement thereof may be limited by bankruptcy,
insolvency, reorganization, moratorium, fraudulent conveyance or other similar laws affecting the enforcement of creditors’
rights generally, and there exists no event or condition which will result in a material violation or breach of or constitute (with
or without due notice or lapse of time or both) a default by the Company or any of its Subsidiaries under any such License Agreement.

 

(c)   
The Company and its Subsidiaries own or have the valid right to use all of the Intellectual Property that is necessary
for the conduct of the Company’s and each of its Subsidiaries’ respective businesses as currently conducted or as currently
proposed to be conducted and for the ownership, maintenance and operation of the Company’s and its Subsidiaries’ properties
and assets, free and clear of all liens, encumbrances, adverse claims or obligations to license all such owned Intellectual Property
and Confidential Information, other than licenses entered into in the ordinary course of the Company’s and its Subsidiaries’
businesses. The Company and its Subsidiaries have a valid and enforceable right to use all third party Intellectual Property and
Confidential Information used or held for use in the respective businesses of the Company and its Subsidiaries.

    	-10-

    	 

    
 

(d)   
Except as disclosed in the SEC Filings or on Schedule 4.15, the conduct of the Company’s and its Subsidiaries’
businesses as currently conducted does not infringe or otherwise impair or conflict with (collectively, “Infringe”)
any Intellectual Property rights of any third party or any confidentiality obligation owed to a third party, and, to the Company’s
Knowledge, the Intellectual Property and Confidential Information of the Company and its Subsidiaries which are necessary for the
conduct of Company’s and each of its Subsidiaries’ respective businesses as currently conducted or as currently proposed
to be conducted are not being Infringed by any third party. There is no litigation or order pending or outstanding or, to the Company’s
Knowledge, threatened or imminent, that seeks to limit or challenge or that concerns the ownership, use, validity or enforceability
of any Intellectual Property or Confidential Information of the Company and its Subsidiaries and the Company’s and its Subsidiaries’
use of any Intellectual Property or Confidential Information owned by a third party, and, to the Company’s Knowledge, there
is no valid basis for the same.

 

(e)   
The consummation of the transactions contemplated hereby and by the Registration Rights Agreement will not result
in the alteration, loss, impairment of or restriction on the Company’s or any of its Subsidiaries’ ownership or right
to use any of the Intellectual Property or Confidential Information which is necessary for the conduct of Company’s and each
of its Subsidiaries’ respective businesses as currently conducted or as currently proposed to be conducted.

 

(f)   
The Company and its Subsidiaries have taken reasonable steps to protect the Company’s and its Subsidiaries’
rights in their Intellectual Property and Confidential Information. To the Company’s Knowledge, except under confidentiality
obligations, there has been no material disclosure of any of the Company’s or its Subsidiaries’ Confidential Information
to any third party.

 

4.16         
Environmental Matters. Neither the Company nor any Subsidiary (a) is in material violation of any statute,
rule, regulation, decision or order of any governmental agency or body or any court, domestic or foreign, relating to the use,
disposal or release of hazardous or toxic substances or relating to the protection or restoration of the environment or human exposure
to hazardous or toxic substances (collectively, “Environmental Laws”), (b) owns or operates any real property
contaminated with any substance that is subject to any Environmental Laws, (c) is liable for any off-site disposal or contamination
pursuant to any Environmental Laws, or (d) is subject to any claim relating to any Environmental Laws, which violation, contamination,
liability or claim has had or could reasonably be expected to have a Material Adverse Effect, individually or in the aggregate.
There is no pending or, to the Company’s Knowledge, threatened investigation that might lead to any claim described in items
(a) through (d) of this Section 4.16.

    	-11-

    	 

    
 

4.17         
Litigation. There are no pending actions, suits or proceedings against or affecting the Company, its Subsidiaries
or any of its or their properties; and to the Company’s Knowledge, no such actions, suits or proceedings are threatened or
contemplated. Except as disclosed in the SEC Filings or on Schedule 4.17, neither the Company nor any Subsidiary, nor any
director or officer thereof, is or since January 1, 2007 has been the subject of any action involving a claim of violation of or
liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the Company’s
Knowledge, there is not pending or contemplated, any investigation by the SEC involving the Company or any current or former director
or officer of the Company. The SEC has not issued any stop order or other order suspending the effectiveness of any registration
statement filed by the Company or any Subsidiary under the 1933 Act or the 1934 Act.

 

4.18         
Financial Statements. The financial statements included in each SEC Filing comply in all material respects
with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time
of filing (or to the extent corrected by a subsequent restatement) and present fairly, in all material respects, the consolidated
financial position of the Company as of the dates shown and its consolidated results of operations and cash flows for the periods
shown, and such financial statements have been prepared in conformity with United States generally accepted accounting principles
applied on a consistent basis (“GAAP”) (except as may be disclosed therein or in the notes thereto, and, in
the case of quarterly financial statements, as permitted by Form 10-Q under the 1934 Act). Except as set forth in the financial
statements of the Company included in the SEC Filings filed prior to the date hereof or as described on Schedule 4.18, neither
the Company nor any of its Subsidiaries has incurred any liabilities, contingent or otherwise, except those incurred in the ordinary
course of business, consistent (as to amount and nature) with past practices, since the date of such financial statements, none
of which, individually or in the aggregate, have had or could reasonably be expected to have a Material Adverse Effect.

 

4.19         
Insurance Coverage. The Company and each Subsidiary maintains in full force and effect insurance coverage
that is customary for comparably situated companies for the business being conducted and properties owned or leased by the Company
and each Subsidiary, and the Company reasonably believes such insurance coverage to be adequate against all liabilities, claims
and risks against which it is customary for comparably situated companies to insure.

 

4.20         
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq
continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company
relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s
Knowledge is there any basis for, the delisting of the Common Stock from Nasdaq.

 

4.21         
Brokers and Finders. No Person will have, as a result of the transactions contemplated by the Transaction
Documents, any valid right, interest or claim against or upon the Company, any Subsidiary or an Investor for any commission, fee
or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company, other
than the Agents as described in Schedule 4.21.

    	-12-

    	 

    
 

4.22         
No Directed Selling Efforts or General Solicitation. Neither the Company nor any Person acting on its behalf
has conducted any general solicitation or general advertising (as those terms are used in Regulation D) in connection with the
offer or sale of any of the Shares.

 

4.23         
No Integrated Offering. Neither the Company nor any of its Affiliates, nor any Person acting on its or their
behalf has, directly or indirectly, made any offers or sales of any Company security or solicited any offers to buy any security,
under circumstances that would adversely affect reliance by the Company on Section 4(2) for the exemption from registration for
the transactions contemplated hereby or would require registration under the 1933 Act of the offer and sale of the Shares pursuant
to this Agreement.

 

4.24         
Private Placement. The offer and sale of the Shares to the Investors as contemplated hereby is exempt from
the registration requirements of the 1933 Act.

 

4.25         
Questionable Payments. Neither the Company nor any of its Subsidiaries nor, to the Company’s
Knowledge, any of their respective current or former stockholders, directors, officers, employees, agents or other Persons acting
on behalf of the Company or any Subsidiary, has on behalf of the Company or any Subsidiary or in connection with their respective
businesses: (a) used any corporate funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating to
political activity; (b) made any direct or indirect unlawful payments to any governmental officials or employees from corporate
funds; (c) established or maintained any unlawful or unrecorded fund of corporate monies or other assets; (d) made any false or
fictitious entries on the books and records of the Company or any Subsidiary; or (e) made any unlawful bribe, rebate, payoff, influence
payment, kickback or other unlawful payment of any nature.

 

4.26         
Transactions with Affiliates. Except as disclosed in the SEC Filings, none of the officers or directors of
the Company and, to the Company’s Knowledge, none of the employees of the Company is presently a party to any transaction
with the Company or any Subsidiary (other than as holders of stock options and/or warrants, and for services as employees, officers
and directors) of the type required to be disclosed in any existing or future SEC Filing pursuant to Item 404 of the SEC’s
Regulation S-K.

    	-13-

    	 

    
 

4.27         
Internal Controls. The Company is in material compliance with the provisions
of the Sarbanes-Oxley Act of 2002 currently applicable to the Company. The Company and the Subsidiaries maintain a system
of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with
management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance
with management’s general or specific authorization, and (iv) the recorded accountability for assets is compared with the
existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company has established
disclosure controls and procedures (as defined in 1934 Act Rules 13a-15(e) and 15d-15(e)) for the Company and designed such disclosure
controls and procedures to ensure that material information relating to the Company, including the Subsidiaries, is made known
to the certifying officers by others within those entities, particularly during the period in which the Company’s most recently
filed periodic report under the 1934 Act, as the case may be, is being prepared. The Company’s certifying officers have evaluated
the effectiveness of the Company’s controls and procedures as of the end of the period covered by the most recently filed
periodic report under the 1934 Act (such date, the “Evaluation Date”). The Company presented in its most recently
filed periodic report under the 1934 Act the conclusions of the certifying officers about the effectiveness of the disclosure controls
and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no significant
changes in the Company’s internal control over financial reporting (as such term is defined in Item 308 of Regulation S-K)
or, to the Company’s Knowledge, in other factors that could significantly affect the Company’s internal control over
financial reporting. The Company maintains and will continue to maintain a standard system of accounting established and administered
in accordance with GAAP and the applicable requirements of the 1934 Act.

 

4.28         
Disclosures. Neither the Company nor any Person acting on its behalf has provided the Investors or their agents
or counsel with any information that constitutes or might constitute material, non-public information, other than (i) the terms
of the transactions contemplated hereby and (ii) certain information contained in the Company’s investor presentation (the
“Other Data”). The written materials delivered to the Investors in connection with the transactions contemplated by
the Transaction Documents do not contain any untrue statement of a material fact or omit to state a material fact necessary in
order to make the statements contained therein, in light of the circumstances under which they were made, not misleading.

 

4.29         
Investment Company. The Company is not required to be registered as, and is not an Affiliate of, and immediately
following the Closing will not be required to register as, an “investment company” within the meaning of the
Investment Company Act of 1940, as amended.

 

5.                 
Representations and Warranties of the Investors. Each of the Investors hereby severally, and not jointly,
represents and warrants to the Company that:

 

5.1             
Organization and Existence. If an entity, such Investor is duly organized, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or organization as set forth below such Investor’s name on the signature
page hereof with the requisite power and authority to purchase the Shares to be purchased by it hereunder and to execute and deliver
this Agreement and Registration Rights Agreement.

 

5.2             
Authorization. Assuming the due authorization, execution and delivery thereof by the Company, the Transaction
Documents constitute such Investor’s valid and legally binding obligation, enforceable against such Investor in accordance
with their respective terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws
of general applicability, relating to or affecting creditors’ rights generally.

    	-14-

    	 

    
 

5.3             
Purchase Entirely for Own Account. The Shares to be received by such Investor hereunder will be acquired for
such Investor’s own account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof
in violation of the 1933 Act, and such Investor has no present intention of selling, granting any participation in, or otherwise
distributing the same in violation of the 1933 Act without prejudice, however, to such Investor’s
right at all times to sell or otherwise dispose of all or any part of such Shares in compliance with applicable federal and state
securities laws. Nothing contained herein shall be deemed a representation or warranty
by such Investor to hold the Shares for any period of time. Such Investor is not a broker-dealer registered with the SEC
under the 1934 Act or an entity engaged in a business that would require it to be so registered.

 

5.4             
Investment Experience. Such Investor acknowledges that it can bear the economic risk and complete loss of
its investment in the Shares and has such knowledge and experience in financial or business matters that it is capable of evaluating
the merits and risks of the investment contemplated hereby.

 

5.5             
Disclosure of Information. Such Investor has had an opportunity to receive all information related to the
Company requested by it and to ask questions of and receive answers from the Company regarding the Company, its business and the
terms and conditions of the offering of the Shares. Such Investor acknowledges receipt of copies of the SEC Filings. Neither such
inquiries nor any other due diligence investigation conducted by such Investor shall modify, limit or otherwise affect such Investor’s
right to rely on the Company’s representations and warranties contained in this Agreement. Such Investor understands that
no United States federal or state agency or any other government or governmental agency has passed on or made any recommendation
or endorsement of the Shares or the fairness or suitability of the investment in the Shares, nor have such authorities passed upon
or endorsed the merits of the offering of the Shares.

 

5.6             
Restricted Securities. Such Investor understands that the Shares are characterized as “restricted
securities” under the U.S. federal securities laws inasmuch as they are being acquired from the Company in a transaction
not involving a public offering and that under such laws and applicable regulations such securities may be resold without registration
under the 1933 Act only in certain limited circumstances. Without limiting the scope of the foregoing, such Investor acknowledges
that the Shares have not been and, except as provided in the Registration Rights Agreement, are not being registered under the
1933 Act and may not be transferred or resold without registration under the 1933 Act or unless pursuant to an exemption therefrom.

    	-15-

    	 

    
 

5.7             
Legends. It is understood that, except as provided in Section 7.7 of this Agreement, certificates evidencing
the Shares will bear the following legends:

 

(a)   
“The securities represented hereby have not been registered with the
Securities and Exchange Commission or the securities commission of any state in reliance upon an exemption from registration under
the Securities Act of 1933, as amended, and, accordingly, may not be transferred unless (i) such securities have been registered
for sale pursuant to the Securities Act of 1933, as amended, (ii) such securities may be sold pursuant to Rule 144, or (iii) the
Company has received an opinion of counsel reasonably satisfactory to it that such transfer may lawfully be made without registration
under the Securities Act of 1933, as amended.”

 

(b)   
If required by the authorities of any state in connection with the issuance of sale of the Shares, the legend required
by such state authority.

 

5.8             
Accredited Investor. Such Investor is an accredited investor as defined in Rule 501(a) of Regulation D, as
amended, under the 1933 Act, as amended by the Dodd-Frank Wall Street Reform and Consumer Protection Act, and, prior to the Closing,
has delivered to the Company a true and correct letter, in the form attached hereto as Exhibit B, identifying the basis
for its accredited investor status.

 

5.9             
No General Solicitation. Such Investor did not learn of the investment in the Shares as a result of any general
solicitation or general advertising.

 

5.10         
 Reliance on Representations. Such Investor understands that the Shares are being offered and sold to the Investor
in reliance upon specific exemptions from the registration requirements of the 1933 Act and state securities laws and that the
Company is relying upon the truth and accuracy of the representations and warranties of such Investor set forth in this Section
5 to determine the availability of such exemptions and the eligibility of such Investor to acquire the Shares.

 

5.11         
 Brokers and Finders. No Person will have, as a result of the transactions contemplated by the Transaction
Documents, any valid right, interest or claim against or upon the Company, any Subsidiary or an Investor for any commission, fee
or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of such Investor.

 

5.12         
 Prohibited Transactions. Since the earlier of (a) such time as such Investor was first contacted by
the Company or any other Person acting on behalf of the Company regarding the transactions contemplated hereby or (b) thirty (30)
days prior to the date hereof, neither such Investor nor any Affiliate of such Investor which (x) had knowledge of the transactions
contemplated hereby, (y) has or shares discretion relating to such Investor’s investments or trading or information concerning
such Investor’s investments, including in respect of the Shares, or (z) is subject to such Investor’s review or input
concerning such Affiliate’s investments or trading (collectively, “Trading Affiliates”) has, directly
or indirectly, effected or agreed to effect any short sale, whether or not against the box, established any “put equivalent
position” (as defined in Rule 16a-1(h) under the 1934 Act) with respect to the Common Stock, granted any other right
(including, without limitation, any put or call option) with respect to the Common Stock or with respect to any security that
includes, relates to or derived any significant part of its value from the Common Stock or otherwise sought to hedge its position
in the Shares (each, a “Prohibited Transaction”). Prior to the earliest to occur of (i) the termination of
this Agreement, (ii) the Effective Date or (iii) the Effectiveness Deadline, such Investor shall not, and shall cause its Trading
Affiliates not to, engage, directly or indirectly, in a Prohibited Transaction. Such Investor acknowledges that the representations,
warranties and covenants contained in this Section 5.12 are being made for the benefit of the Investors as well as the Company
and that each of the other Investors shall have an independent right to assert any claims against such Investor arising out of
any breach or violation of the provisions of this Section 5.12.

    	-16-

    	 

    
 

5.13         
Agents. Such Investor understands that the Agents have acted solely as the agents of the Company in this placement
of the Shares, and that no Agent makes any representation or warranty with regard to the merits of this transaction or as to the
accuracy of any information such Investor may have received in connection therewith. Such Investor acknowledges that he has not
relied on any information or advice furnished by or on behalf of any Agent.

 

6.                 
Conditions to Closing.

 

6.1            
Conditions to the Investors’ Obligations. The obligation of each Investor to purchase its Shares at
the Closing is subject to the fulfillment to such Investor’s satisfaction, on or prior to the Closing Date, of the following
conditions, any of which may be waived by such Investor (as to itself only):

 

(a)   
The representations and warranties made by the Company in Section 4 hereof qualified as to materiality shall be true
and correct at all times prior to and on the Closing Date, except to the extent any such representation or warranty expressly speaks
as of an earlier date, in which case such representation or warranty shall be true and correct as of such earlier date, and, the
representations and warranties made by the Company in Section 4 hereof not qualified as to materiality shall be true and correct
in all material respects at all times prior to and on the Closing Date, except to the extent any such representation or warranty
expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in all material
respects as of such earlier date. The Company shall have performed in all material respects all obligations and covenants herein
required to be performed by it on or prior to the Closing Date.

 

(b)   
The Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary or
appropriate for consummation of the purchase and sale of the Shares and the consummation of the other transactions contemplated
by the Transaction Documents, all of which shall be in full force and effect.

 

(c)   
The Company shall have executed and delivered the Registration Rights Agreement.

    	-17-

    	 

    
 

(d)   
The Company shall have filed with Nasdaq a Notification Form: Listing of Additional Shares for the listing of the
Shares on Nasdaq, a copy of which shall have been provided to the Investors.

 

(e)   
No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including
any bankruptcy court or judge, or any order of or by any governmental authority, shall have been issued, and no action or proceeding
shall have been instituted by any governmental authority, enjoining or preventing the consummation of the transactions contemplated
hereby or by the Registration Rights Agreement.

 

(f)   
The Company shall have delivered a Certificate, executed on behalf of the Company by its Chief Executive Officer
or its Chief Financial Officer, dated as of the Closing Date, certifying to the fulfillment of the conditions specified in subsections
(a), (b), (d), (e) and (i) of this Section 6.1.

 

(g)   
The Company shall have delivered a Certificate, executed on behalf of the Company by its Secretary, dated as of the
Closing Date, certifying the resolutions adopted by the Board of Directors of the Company approving the transactions contemplated
by this Agreement and the Registration Rights Agreement, the issuance of the Shares and the Restructuring, certifying the current
versions of the Certificate of Incorporation and Bylaws of the Company and certifying as to the signatures and authority of persons
signing the Transaction Documents and related documents on behalf of the Company.

 

(h)   
The Investors shall have received an opinion from Gordon Feinblatt LLC, the Company’s counsel, dated as of
the Closing Date, in form and substance reasonably acceptable to the Investors and addressing such legal matters as the Investors
may reasonably request.

 

(i)   
No stop order or suspension of trading shall have been imposed by Nasdaq, the SEC or any other governmental or regulatory
body with respect to public trading in the Common Stock.

 

6.2             
Conditions to Obligations of the Company. The Company’s obligation to sell and issue the Shares at the
Closing is subject to the fulfillment to the satisfaction of the Company on or prior to the Closing Date of the following conditions,
any of which may be waived by the Company:

 

(a)   
The representations and warranties made by the Investors in Section 5 hereof, other than the representations and
warranties contained in Sections 5.3, 5.4, 5.5, 5.6, 5.7, 5.8 and 5.9 (the “Investment Representations”), shall
be true and correct in all material respects when made, and shall be true and correct in all material respects on the Closing Date
with the same force and effect as if they had been made on and as of said date. The Investment Representations shall be true and
correct in all respects when made, and shall be true and correct in all respects on the Closing Date with the same force and effect
as if they had been made on and as of said date. The Investors shall have performed in all material respects all obligations and
covenants herein required to be performed by them on or prior to the Closing Date.

    	-18-

    	 

    
 

(b)   
Each of the Investors shall have executed and delivered the Registration Rights Agreement.

 

(c)   
Each of the Investors shall have delivered the Purchase Price to the Company.

 

6.3             
Termination of Obligations to Effect Closing; Effects.

 

 

(a)   
The obligations of the Company, on the one hand, and the Investors, on the other hand, to effect the Closing shall
terminate as follows:

 

(b)   
Upon the mutual written consent of the Company and the Investors;

 

(c)   
By the Company if any of the conditions set forth in Section 6.2 shall have become incapable of fulfillment, and
shall not have been waived by the Company;

 

(d)   
By an Investor (with respect to itself only) if any of the conditions set forth in Section 6.1 shall have become
incapable of fulfillment, and shall not have been waived by the Investor; or

 

(e)   
By either the Company or any Investor (with respect to itself only) if the Closing has not occurred on or prior to
October 15, 2012;

 

provided, however,
that, except in the case of clause (b) above, the party seeking to terminate its obligation to effect the Closing shall not then
be in breach of any of its representations, warranties, covenants or agreements contained in this Agreement or the Registration
Rights Agreement if such breach has resulted in the circumstances giving rise to such party’s seeking to terminate its obligation
to effect the Closing.

 

(f)   
In the event of termination by the Company or any Investor of its obligations to effect the Closing pursuant to this
Section 6.4, written notice thereof shall forthwith be given to the other Investors by the Company and the other Investors shall
have the right to terminate their obligations to effect the Closing upon written notice to the Company and the other Investors.
Nothing in this Section 6.4 shall be deemed to release any party from any liability for any breach by such party of the terms and
provisions of this Agreement or the Registration Rights Agreement or to impair the right of any party to compel specific performance
by any other party of its obligations under this Agreement or the Registration Rights Agreement.

    	-19-

    	 

    
 

7.                 
Covenants and Agreements of the Company.

 

7.1             
Reports. The Company will furnish to the Investors and/or their assignees such information relating to the
Company and its Subsidiaries as from time to time may reasonably be requested by the Investors and/or their assignees; provided,
however, that the Company shall not disclose material nonpublic information to the Investors, or to advisors to or representatives
of the Investors, unless prior to disclosure of such information the Company identifies such information as being material nonpublic
information and provides the Investors, such advisors and representatives with the opportunity to accept or refuse to accept such
material nonpublic information for review and any Investor wishing to obtain such information enters into an appropriate confidentiality
agreement with the Company with respect thereto.

 

7.2             
No Conflicting Agreements. The Company will not take any action, enter into any agreement or make any commitment
that would conflict or interfere in any material respect with the Company’s obligations to the Investors under the Transaction
Documents.

 

7.3             
Insurance. The Company shall not materially reduce the insurance coverages described in Section 4.19.

 

7.4             
Compliance with Laws. The Company will comply in all material respects with all applicable laws, rules, regulations,
orders and decrees of all governmental authorities.

 

7.5             
Listing of Shares and Related Matters. Promptly following the date hereof, the Company shall take all necessary
action to cause the Shares to be listed on Nasdaq no later than the Closing Date. Further, if the Company applies to have its Common
Stock traded on any other principal stock exchange or market, it shall include in such application the Shares and will take such
other action as is necessary to cause such Shares to be so listed. The Company will use commercially reasonable efforts to continue
the listing and trading of its Common Stock on Nasdaq and, in accordance, therewith, will use commercially reasonable efforts to
comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules of such market
or exchange, as applicable.

 

7.6             
Termination of Covenants. The provisions of Sections 7.1 through 7.4 shall terminate and be of no further
force and effect on the date on which the Company’s obligations under the Registration Rights Agreement to register or maintain
the effectiveness of any registration covering the Registrable Securities (as such term is defined in the Registration Rights Agreement)
shall terminate.

    	-20-

    	 

    
 

7.7             
Removal of Legends. In connection with any sale or disposition of the Shares by an Investor pursuant to Rule
144 or pursuant to any other exemption under the 1933 Act such that the purchaser acquires freely tradable shares and upon compliance
by the Investor with the requirements of this Agreement, the Company shall cause the transfer agent for the Common Stock (the “Transfer
Agent”) to issue replacement certificates representing the Shares sold or disposed of without restrictive legends. Upon
the earlier of (i) registration for resale pursuant to the Registration Rights Agreement or (ii) the Shares becoming freely tradable
by a non-affiliate pursuant to Rule 144 the Company shall (A) deliver to the Transfer Agent irrevocable instructions that the Transfer
Agent shall reissue a certificate representing shares of Common Stock without legends upon receipt by such Transfer Agent of the
legended certificates for such shares, together with (1) either a customary representation by the Investor that Rule 144 applies
to the shares of Common Stock represented thereby or (2) a statement by the Investor that such Investor has sold the shares of
Common Stock represented thereby in accordance with the Plan of Distribution contained in the Registration Statement, and (B) cause
its counsel to deliver to the Transfer Agent one or more blanket opinions to the effect that the removal of such legends in such
circumstances may be effected under the 1933 Act. From and after the earlier of such dates, upon an Investor’s written request,
the Company shall promptly cause certificates evidencing the Investor’s Shares to be replaced with certificates which do
not bear such restrictive legends. When the Company is required to cause an unlegended certificate to replace a previously issued
legended certificate, if: (1) the unlegended certificate is not delivered to an Investor within three (3) Business Days of submission
by that Investor of a legended certificate and supporting documentation to the Transfer Agent as provided above and (2) prior to
the time such unlegended certificate is received by the Investor, the Investor, or any third party on behalf of such Investor or
for the Investor’s account, purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction
of a sale by the Investor of shares represented by such certificate (a “Buy-In”), then the Company shall pay
in cash to the Investor (for costs incurred either directly by such Investor or on behalf of a third party) the amount by which
the total purchase price paid for Common Stock as a result of the Buy-In (including brokerage commissions, if any) exceeds the
proceeds received by such Investor as a result of the sale to which such Buy-In relates. The Investor shall provide the Company
written notice indicating the amounts payable to the Investor in respect of the Buy-In.

 

7.8             
Subsequent Equity Sales.

 

(a)   
From the date hereof until ninety (90) days after the Closing Date, without the consent of the Required Investors,
neither the Company nor any Subsidiary shall issue shares of Common Stock or Common Stock Equivalents. Notwithstanding the foregoing,
the provisions of this Section 7.8(a) shall not apply to (i) the issuance of Common Stock or Common Stock Equivalents upon the
conversion, exercise or exchange of any securities of the Company or a Subsidiary outstanding on the date hereof, provided that
the terms of such security are not amended after the date hereof to decrease the exercise price or increase the Common Stock or
Common Stock Equivalents receivable upon the exercise, conversion or exchange thereof or (ii) the issuance of any Common Stock
or Common Stock Equivalents pursuant to any Stock Plans.

    	-21-

    	 

    
 

(b)   
From the date hereof until the earlier of (i) two years from the Closing Date or (ii) such time as no Investor holds
any of the Shares, the Company shall be prohibited from effecting or entering into an agreement to effect any “Variable
Rate Transaction”. The term “Variable Rate Transaction” shall mean a transaction, other than an Exempt
Transaction (as defined below), in which the Company (A) issues or sells any debt or equity securities that are convertible into,
exchangeable or exercisable for, or include the right to receive additional shares of Common Stock either (x) at a conversion,
exercise or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the shares
of Common Stock at any time after the initial issuance of such debt or equity securities, or (y) with a conversion, exercise or
exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security or
upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market
for the Common Stock or (B) enters into any agreement, including, but not limited to, an equity line of credit, whereby the Company
may sell securities at a future determined price. For the avoidance of doubt, the issuance of a security which is subject to customary
anti-dilution protections, including where the conversion, exercise or exchange price is subject to adjustment as a result of stock
splits, reverse stock splits and other similar recapitalization or reclassification events, shall not be deemed to be a “Variable
Rate Transaction.” As used in this Section 7.8(b), “Exempt Transaction” shall mean (i) the issuance
and exercise of any awards pursuant to the Stock Plans and (ii) the issuance of any security of the Company upon the vesting, conversion,
exchange or exercise of any other security of the Company outstanding on the date of this Agreement in accordance with the terms
of such other security, provided, that such other security are not amended after the date hereof to increase the amount of securities
issuable thereunder or to lower the conversion, exchange or exercise price thereof.

 

(c)   
The Company shall not, and shall use its commercially reasonable efforts to ensure that no Affiliate of the Company
shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2
of the 1933 Act) that will be integrated with the offer or sale of the Shares in a manner that would require the registration under
the 1933 Act of the sale of the Shares to the Investors, or that will be integrated with the offer or sale of the Shares for purposes
of the rules and regulations of any trading market such that it would require stockholder approval prior to the closing of such
other transaction unless stockholder approval is obtained before the closing of such subsequent transaction.

 

7.9             
Equal Treatment of Investors. No consideration shall be offered or paid to any Person to amend or consent
to a waiver or modification of any provision of any of the Transaction Documents unless the same consideration is also offered
to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate right granted
to each Investor by the Company and negotiated separately by each Investor, and is intended for the Company to treat the Investors
as a class and shall not in any way be construed as the Investors acting in concert or as a group with respect to the purchase,
disposition or voting of Shares or otherwise.

 

8.                 
Survival and Indemnification.

 

8.1             
Survival. The representations, warranties, covenants and agreements contained in this Agreement shall survive
the Closing of the transactions contemplated by this Agreement.

    	-22-

    	 

    
 

8.2             
Indemnification. The Company agrees to indemnify and hold harmless each Investor and its Affiliates and their
respective directors, officers, trustees, members, managers, employees and agents, and their respective successors and assigns,
from and against any and all losses, claims, damages, liabilities and expenses (including without limitation reasonable attorney
fees and disbursements and other expenses incurred in connection with investigating, preparing or defending any action, claim or
proceeding, pending or threatened and the costs of enforcement thereof) to which such Person may become subject as a result of
any breach of representation, warranty, covenant or agreement made by or to be performed on the part of the Company under the Transaction
Documents, and will reimburse any such Person for all such amounts as they are incurred by such Person.

 

8.3             
Conduct of Indemnification Proceedings. Any Person entitled to indemnification hereunder shall
(a) give prompt notice to the indemnifying party of any claim with respect to which it seeks indemnification and (b) permit such
indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party; provided
that any Person entitled to indemnification hereunder shall have the right to employ separate counsel and to participate in the
defense of such claim, but the fees and expenses of such counsel shall be at the expense of such person unless (i) the indemnifying
party has agreed to pay such fees or expenses, or (ii) the indemnifying party shall have failed to assume the defense of such claim
and employ counsel reasonably satisfactory to such person or (iii) in the reasonable judgment of any such Person, based upon written
advice of its counsel, a conflict of interest exists between such Person and the indemnifying party with respect to such claims
(in which case, if the Person notifies the indemnifying party in writing that such person elects to employ separate counsel at
the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf
of such Person); and provided further that the failure of any indemnified party to give notice as provided herein
shall not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall
materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying
party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate
firm of attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified
party, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the
giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect of such claim or litigation.

 

9.                 
Miscellaneous.

 

9.1             
Successors and Assigns. This Agreement may not be assigned by a party hereto without the prior written consent
of the Company or the Investors, as applicable, provided, however, that an Investor may assign its rights and delegate
its duties hereunder in whole or in part to an Affiliate or to a third party acquiring some or all of its Shares in a transaction
complying with applicable securities laws without the prior written consent of the Company or the other Investors. The provisions
of this Agreement shall inure to the benefit of and be binding upon the respective permitted successors and assigns of the parties.
Without limiting the generality of the foregoing, in the event that the Company is a party to a merger, consolidation, share exchange
or similar business combination transaction in which the Common Stock is converted into the equity securities of another Person,
from and after the effective time of such transaction, such Person shall, by virtue of such transaction, be deemed to have assumed
the obligations of the Company hereunder, the term “Company” shall be deemed to refer to such Person and the
term “Shares” shall be deemed to refer to the securities received by the Investors in connection with such transaction.
Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective
successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly
provided in this Agreement.

    	-23-

    	 

    
 

9.2             
Counterparts; Facsimile. This Agreement may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. The exchange of copies of this Agreement
and of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery of this Agreement as
to the Parties and may be used in lieu of an original of this Agreement for all purposes. Signatures of the Parties transmitted
by facsimile or PDF transmission shall be deemed to be their original signatures for all purposes.

 

9.3             
Titles and Subtitles; Construction. The titles and subtitles used in this Agreement are used for convenience
only. They form no part of this Agreement and shall not affect its construction or interpretation. All references to Sections,
subsections, paragraphs, clauses or other subdivisions in this Agreement refer to the corresponding Sections, subsections, paragraphs,
clauses or other subdivisions of this Agreement. All words used in this Agreement shall be construed to be of such gender or number
as the circumstances require. As used in this Agreement, the words “hereby”, “herein”, hereof”, “hereunder”
and words of similar import refer to this Agreement as a whole and not to any particular provision of this Agreement.

 

9.4             
Notices. Unless otherwise provided, any notice required or permitted under this Agreement shall be given in
writing and shall be deemed effectively given as hereinafter described (a) if given by personal delivery, then such notice shall
be deemed given upon such delivery, (b) if given by telex or telecopier, then such notice shall be deemed given upon receipt of
confirmation of complete transmittal, (c) if given by mail, then such notice shall be deemed given upon the earlier of (A) receipt
of such notice by the recipient or (B) three days after such notice is deposited in first class mail, postage prepaid, and (d)
if given by an internationally recognized overnight air courier, then such notice shall be deemed given one Business Day after
delivery to such carrier. All notices shall be addressed to the party to be notified at the address as follows, or at such other
address as such party may designate by ten days’ advance written notice to the other party:

 

                               If to the Company:

 

Crumbs Bake Shop, Inc.

110 West 40th Street, Suite 2100

New York, NY 10018

Attention: Julian Geiger, Chief Executive Officer

Fax:

    	-24-

    	 

    
 

                               With a copy to:

 

Gordon Feinblatt LLC

233 East Redwood Street

Baltimore, MD 21202

Attention: Andrew D. Bulgin, Esq.

Fax: (410) 576-4196

 

                               If to the Investors:

 

                                                to the addresses set forth on the signature
pages hereto.

 

9.5             
Expenses. The parties hereto shall pay their own costs and expenses in connection herewith, except that the
Company shall pay the reasonable, documented fees and expenses of Lowenstein Sandler PC, not to exceed $40,000, incurred or to
be incurred by the Special Situations Funds participating in this transaction in connection with the negotiation, preparation,
execution and delivery of this Agreement and the Registration Rights Agreement, regardless of whether the transactions contemplated
hereby are consummated; it being understood that Lowenstein Sandler PC has only rendered legal advice to the Special Situations
Funds participating in this transaction and not to the Company or any other Investor in connection with the transactions contemplated
hereby, and that each of the Company and each Investor has relied for such matters on the advice of its own respective counsel.
Such expenses shall be paid upon demand and presentment to the Company of an invoice for the same. The Company shall reimburse
the Investors upon demand for all reasonable out-of-pocket expenses incurred by the Investors, including without limitation reimbursement
of attorneys’ fees and disbursements, in connection with any amendment, modification or waiver of this Agreement or the Registration
Rights Agreement requested by the Company. In the event that legal proceedings are commenced by any party to this Agreement against
another party to this Agreement in connection with this Agreement or the Registration Rights Agreement, or the transactions contemplated
hereby or thereby, the party or parties which do not prevail in such proceedings shall severally, but not jointly, pay their pro
rata share of the reasonable attorneys’ fees and other reasonable out-of-pocket costs and expenses incurred by the prevailing
party in such proceedings.

 

9.6             
Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement
may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent
of the Company and the Required Investors. Any amendment or waiver effected in accordance with this Section 9.6 shall be binding
upon each holder of any Shares purchased under this Agreement at the time outstanding, each future holder of all such Shares, and
the Company.

    	-25-

    	 

    
 

9.7             
Publicity. Except as set forth below, no public release or announcement concerning the transactions contemplated
hereby shall be issued by the Company or the Investors without the prior consent of the Company (in the case of a release or announcement
by the Investors) or the Investors (in the case of a release or announcement by the Company) (which consents shall not be unreasonably
withheld), except as such release or announcement may be required by law or the applicable rules or regulations of any securities
exchange or securities market, in which case the Company or the Investors, as the case may be, shall allow the Investors or the
Company, as applicable, to the extent reasonably practicable in the circumstances, reasonable time to comment on such release or
announcement in advance of such issuance. By 8:30 a.m. (New York City time) on the trading day immediately following the execution
and delivery of this Agreement by the parties hereto (the “Disclosure Deadline”), the Company shall issue a press release
disclosing the entry into this Agreement and the transactions contemplated hereby and the Other Data. From and after the Disclosure
Deadline, no Investor will be deemed by the Company to be in possession of any material non-public information and the Investors
will be free to trade in the securities of the Company, subject to (a) restrictions on transfer arising under the 1933 Act and
(b) the provisions of Section 5.12. The Company acknowledges that the Investors will be entitled to rely on the representation
and warranty contained in the foregoing sentence in effecting transactions in the Company’s securities and that such reliance
is reasonable. No later than the fourth trading day following the execution and delivery of this Agreement by the parties hereto,
the Company will file a Current Report on Form 8-K attaching the press release described in the foregoing sentence, the Other Data,
and copies of the Transaction Documents. In addition, the Company will make such other filings and notices in the manner and time
required by the SEC or Nasdaq.

 

9.8             
Severability. Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall,
as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining
provisions hereof but shall be interpreted as if it were written so as to be enforceable to the maximum extent permitted by applicable
law, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision
in any other jurisdiction. To the extent permitted by applicable law, the parties hereby waive any provision of law which renders
any provision hereof prohibited or unenforceable in any respect.

 

9.9             
Entire Agreement. This Agreement, including the Exhibits and the Disclosure Schedules, and the Registration
Rights Agreement constitute the entire agreement among the parties hereof with respect to the subject matter hereof and thereof
and supersede all prior agreements and understandings, both oral and written, between the parties with respect to the subject matter
hereof and thereof.

 

9.10         
Further Assurances. The parties shall execute and deliver all such further instruments and documents and take
all such other actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment
of the agreements herein contained.

    	-26-

    	 

    
 

9.11         
Governing Law; Consent to Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by, and construed
in accordance with, the internal laws of the State of New York without regard to the choice of law principles thereof. Each of
the parties hereto irrevocably submits to the exclusive jurisdiction of the courts of the State of New York located in New York
County and the United States District Court for the Southern District of New York for the purpose of any suit, action, proceeding
or judgment relating to or arising out of this Agreement and the transactions contemplated hereby. Service of process in connection
with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified
for the giving of notices under this Agreement. Each of the parties hereto irrevocably consents to the jurisdiction of any such
court in any such suit, action or proceeding and to the laying of venue in such court. Each party hereto irrevocably waives any
objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim
that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum.  EACH OF THE PARTIES
HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT COUNSEL
HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.

 

9.12         
Independent Nature of Investors’ Obligations and Rights. The obligations of each Investor under any
Transaction Document are several and not joint with the obligations of any other Investor, and no Investor shall be responsible
in any way for the performance of the obligations of any other Investor under any Transaction Document. The decision of each Investor
to purchase Shares pursuant to the Transaction Documents has been made by such Investor independently of any other Investor. Nothing
contained herein or in any Transaction Document, and no action taken by any Investor pursuant thereto, shall be deemed to constitute
the Investors as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors
are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction
Documents. Each Investor acknowledges that no other Investor has acted as agent for such Investor in connection with making its
investment hereunder and that no Investor will be acting as agent of such Investor in connection with monitoring its investment
in the Shares or enforcing its rights under the Transaction Documents. Each Investor shall be entitled to independently protect
and enforce its rights, including, without limitation, the rights arising out of this Agreement or out of the Registration Rights
Agreement, and it shall not be necessary for any other Investor to be joined as an additional
party in any proceeding for such purpose. The Company acknowledges that each of the Investors has been provided with the same Transaction
Documents for the purpose of closing a transaction with multiple Investors and not because it was required or requested to do so
by any Investor.

 

9.13         
No Reliance. Each party hereto acknowledges that (a) it has such knowledge in business and financial matters
as to be fully capable of evaluating the Transaction Documents, and the transactions contemplated thereby, (b) it is not relying
on any advice or representation or warranty of any other party hereto in connection with entering into the Transaction Documents
or such transactions (other than the representations and warranties made in the Transaction Documents), (c) it has not received
from any other party hereto any assurance or guarantee as to the merits (whether legal, regulatory, tax, financial or otherwise)
of entering into the Transaction Documents or the performance of its obligations thereunder, and (d) it has consulted with its
own legal, regulatory, tax, business, investment, financial and accounting advisors to the extent that it has deemed necessary,
and has entered into the Transaction Documents based on its own independent judgment and on the advice of its advisors as it has
deemed necessary, and not on any view (whether written or oral) expressed by any other party hereto.

 

 

[Signature Pages Follow]

    	-27-

    	 

    
 

IN WITNESS WHEREOF, the parties have executed
this Agreement or caused their duly authorized officers to execute this Agreement as of the date first above written.

 

	The Company:	CRUMBS BAKE SHOP, INC.
	 	 	 
	 	 	 
	 	 	 
	 	By:	/s/ Julian Geiger                      
	 	Name:	Julian Geiger
	 	Title:	Chief Executive Officer

 

 

 

[Signature Page for Investors Follows]

    	-28-

    	 

    
 

Counterpart
Signature Page

 

 

	FOR ENTITY INVESTORS:	 	FOR INDIVIDUAL INVESTORS:
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	Signature: 	 
	[Name of Entity]	 	Name: 	 
	By:	 	 	Taxpayer ID #: 	 
	Name: 	 	 	 	 
	Title: 	 	 	 	 
	Taxpayer ID #: 	 	 	 	 

 

 

	ADDRESS FOR DELIVERY:	 	ADDRESS FOR NOTICE IF DIFFERENT:
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	Attention: 	 	 	Attention:	 
	Tel: 	 	 	Tel:	 
	Fax: 	 	 	Fax: 	 
	E-mail	 	 	E-mail: 	 

 

	 	With a copy to:	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	Attention: 	 	 
	 	Tel: 	 	 
	 	Fax: 	 	 
	 	E-mail: 	 	 

 

 

	Aggregate Purchase Price:	$_________________	 
	 	 	 
	Shares Purchased:	_________________	 

 

    	-29-

    	 

    
 

LIST OF EXHIBITS AND
SCHEDULES

 

Exhibits

 

Exhibit A – Registration Rights Agreement

Exhibit B – Accredited Investor Letter

 

Schedules

 

Schedule 4.1 – List of Subsidiaries

Schedule 4.3 – Capitalization

Schedule 4.8 – Material Adverse Changes

Schedule 4.11 – Tax Matters

Schedule 4.15 – Intellectual Property
Matters

Schedule 4.17 – Litigation

Schedule 4.18 – Undisclosed Liabilities

Schedule 4.21 – Fees to Agents

    	-30-

    	 

    
 

EXHIBIT A

 

REGISTRATION RIGHTS AGREEMENT

 

This Registration Rights
Agreement (the “Agreement”) is made and entered into as of this 11th day of October, 2012 by and
among Crumbs Bake Shop, Inc., a Delaware corporation (the “Company”), and the “Investors” named in that
certain Purchase Agreement by and among the Company and the Investors (the “Purchase Agreement”).

 

The parties hereby
agree as follows:

 

1.                 
Certain Definitions.

 

In addition to those
terms defined above and elsewhere in this Agreement, the terms set forth below shall, for purposes of this Agreement, have the
respective meanings indicated. Capitalized terms used but not defined herein shall have the respective meanings specified in the
Purchase Agreement.

 

“Common Stock”
means the Company’s common stock, par value $0.0001 per share, and any securities into which such shares may hereinafter
be reclassified.

 

“Investors”
means each investor party to this Agreement and any Affiliate or permitted transferee of any Investor who is a subsequent holder
of any Registrable Securities.

 

“Prospectus”
means (i) the prospectus included in any Registration Statement, as amended or supplemented by any prospectus supplement, with
respect to the terms of the offering of any portion of the Registrable Securities covered by such Registration Statement and by
all other amendments and supplements to the prospectus, including post-effective amendments and all material incorporated by reference
in such prospectus, and (ii) any “free writing prospectus” as defined in Rule 405 under the 1933 Act.

 

“Register,”
“registered” and “registration” refer to a registration made by preparing and filing a Registration
Statement or similar document in compliance with the 1933 Act (as defined below), and the declaration or ordering of effectiveness
of such Registration Statement or document.

 

“Registrable
Securities” means (i) the Shares and (ii) any other securities issued or issuable with respect to or in exchange for
Registrable Securities, whether by merger, charter amendment or otherwise; provided, that, a security shall cease to be a Registrable
Security upon (A) sale of such Registrable Security pursuant to a Registration Statement or Rule 144 under the 1933 Act, (B) with
respect to a Registrable Security held by any particular Person, when such Person is permitted to sell such Registrable Security
without restriction pursuant to Rule 144 or (C) when the Registrable Security is resold to the Company for cash.

 

“Registration
Statement” means any registration statement of the Company filed under the 1933 Act that covers the resale of any of
the Registrable Securities pursuant to the provisions of this Agreement, amendments and supplements to such Registration Statement,
including post-effective amendments, all exhibits and all material incorporated by reference in such Registration Statement.

    	A-1

    	 

    
 

“Required
Investors” means (A) any Investor which, together with its Affiliates, beneficially owns at least 1,000,000 shares of
Common Stock constituting Registrable Securities and (B) the Investors beneficially owning a majority of the Registrable Securities.

 

“SEC”
means the U.S. Securities and Exchange Commission.

 

“1933 Act”
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“1934 Act”
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

2.                 
Registration.

 

(a)               
Registration Statement. Promptly following the closing of the purchase and sale of the Shares contemplated by the
Purchase Agreement (the “Closing Date”) but no later than thirty (30) days after the Closing
Date (the “Filing Deadline”), the Company shall prepare and file with the SEC one Registration Statement on Form S-3
(or, if Form S-3 is not then available to the Company, on such form of registration statement as is then available to effect a
registration for resale of the Registrable Securities), covering the resale of the Registrable Securities. Subject to any
SEC comments, such Registration Statement shall include the plan of distribution attached hereto as Exhibit A; provided,
however, that no Investor shall be named as an “underwriter” in the Registration Statement without the Investor’s
prior written consent. Such Registration Statement shall not include any shares of Common Stock or other securities for the account
of any other holder without the prior written consent of the Required Investors. The Registration Statement (and each amendment
or supplement thereto, and each request for acceleration of effectiveness thereof) shall be provided in accordance with Section
3(c) to the Investors and their counsel prior to its filing or other submission. If a Registration Statement covering the Registrable
Securities is not filed with the SEC on or prior to the Filing Deadline, the Company will make pro rata payments to each Investor,
as liquidated damages and not as a penalty, in an amount equal to 1.5% of the aggregate amount invested by such Investor pursuant
to the Purchase Agreement (or the purchase price of the Registrable Securities purchased by any Person not an original party to
this Agreement) for each 30-day period (or pro rata for any portion thereof) following the Filing Deadline for which no Registration
Statement is filed with respect to the Registrable Securities. Such payments shall constitute the Investors’ exclusive monetary
remedy for such events, but shall not affect the right of the Investors to seek injunctive relief. Such payments shall be made
to each Investor in cash no later than three (3) Business Days after the end of each 30-day period.

 

(b)              
Expenses. The Company will pay all expenses associated with effecting the registration of the Registrable Securities,
including filing and printing fees, the Company’s counsel and accounting fees and expenses, costs associated with clearing
the Registrable Securities for sale under applicable state securities laws, listing fees, and subject to Section 9.5 of the Purchase
Agreement, fees and expenses of one counsel to the Investors, but excluding discounts, commissions, fees of underwriters, selling
brokers, dealer managers or similar securities industry professionals with respect to the Registrable Securities being sold.

    	A-2

    	 

    
 

(c)               
Effectiveness.

 

                                                                
(i)                       
The Company shall use commercially reasonable efforts to have the Registration Statement declared effective as soon as practicable.
The Company shall notify the Investors by facsimile or e-mail as promptly as practicable, and in any event, within twenty-four
(24) hours, after any Registration Statement is declared effective and shall simultaneously provide the Investors with copies of
any related Prospectus to be used in connection with the sale or other disposition of the securities covered thereby. If (A) a
Registration Statement covering the Registrable Securities is not declared effective by the SEC prior to the earlier of (i) five
(5) Business Days after the SEC shall have informed the Company that no review of the Registration Statement will be made or that
the SEC has no further comments on the Registration Statement or (ii) the 90th day after the Closing Date (the 120th
day if the SEC reviews the Registration Statement) or (B) after a Registration Statement has been declared effective by the SEC,
sales cannot be made pursuant to such Registration Statement for any reason (including without limitation by reason of a stop order,
or the Company’s failure to update the Registration Statement), other than because of (i) an Allowed Delay (as defined below)
or (ii) the inability of any Investor to sell the Registrable Securities covered thereby due to market conditions, then the Company
will make pro rata payments to each Investor, as liquidated damages and not as a penalty, in an amount equal to 1.5% of the aggregate
amount invested by such Investor pursuant to the Purchase Agreement (or the purchase price of the Registrable Securities purchased
by any Person not an original party to this Agreement) for each 30- day period (or pro rata for any portion thereof) following
the date by which such Registration Statement should have been effective (the “Blackout Period”). Such payments shall
constitute the Investors’ exclusive monetary remedy for such events, but shall not affect the right of the Investors to seek
injunctive relief. The amounts payable as liquidated damages pursuant to this paragraph shall be paid monthly within three (3)
Business Days of the last day of each month following the commencement of the Blackout Period until the termination of the Blackout
Period. Such payments shall be made to each Investor in cash.

 

                                                              
(ii)                       
For not more than twenty (20) consecutive days or for a total of not more than forty-five (45) days in any twelve (12) month
period, the Company may suspend the use of any Prospectus included in any Registration Statement contemplated by this Section in
the event that the Company determines in good faith that such suspension is necessary to (A) delay the disclosure of material non-public
information concerning the Company, the disclosure of which at the time is not, in the good faith opinion of the Company, in the
best interests of the Company or (B) amend or supplement the affected Registration Statement or the related Prospectus so that
such Registration Statement or Prospectus shall not include an untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements therein, in the case of the Prospectus in light of the circumstances
under which they were made, not misleading (an “Allowed Delay”); provided that the Company shall promptly (a) notify
each Investor in writing of the commencement of an Allowed Delay, but shall not (without the prior written consent of an Investor)
disclose to such Investor any material non-public information giving rise to an Allowed Delay, (b) advise the Investors in writing
to cease all sales under the Registration Statement until the end of the Allowed Delay and (c) use commercially reasonable efforts
to terminate an Allowed Delay as promptly as practicable.

    	A-3

    	 

    
 

(d)              
Rule 415; Cutback If at any time the SEC takes the position that the offering of some or all of the Registrable Securities
in a Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415 under
the 1933 Act or requires any Investor to be named as an “underwriter”, the Company shall use its best efforts to persuade
the SEC that the offering contemplated by the Registration Statement is a valid secondary offering and not an offering “by
or on behalf of the issuer” as defined in Rule 415 and that none of the Investors is an “underwriter”. The Investors
shall have the right to participate or have their counsel participate in any meetings or discussions with the SEC regarding the
SEC’s position and to comment or have their counsel comment on any written submission made to the SEC with respect thereto.
No such written submission shall be made to the SEC to which the Investors’ counsel reasonably objects. In the event that,
despite the Company’s best efforts and compliance with the terms of this Section 2(d), the SEC refuses to alter its position,
the Company shall (i) remove from the Registration Statement such portion of the Registrable Securities (the “Cut Back Shares”)
and/or (ii) agree to such restrictions and limitations on the registration and resale of the Registrable Securities as the SEC
may require to assure the Company’s compliance with the requirements of Rule 415 (collectively, the “SEC Restrictions”);
provided, however, that the Company shall not agree to name any Investor as an “underwriter” in such Registration Statement
without the prior written consent of such Investor. Any cut-back imposed on the Investors pursuant to this Section 2(d) shall be
allocated among the Investors on a pro rata basis, unless the SEC Restrictions otherwise require or provide or the Investors otherwise
agree. No liquidated damages shall accrue as to any Cut Back Shares until such date as the Company is able to effect the registration
of such Cut Back Shares in accordance with any SEC Restrictions (such date, the “Restriction Termination Date” of such
Cut Back Shares). From and after the Restriction Termination Date applicable to any Cut Back Shares, all of the provisions of this
Section 2 (including the liquidated damages provisions) shall again be applicable to such Cut Back Shares; provided, however, that
(i) the Filing Deadline for the Registration Statement including such Cut Back Shares shall be ten (10) Business Days after such
Restriction Termination Date, and (ii) the date by which the Company is required to obtain effectiveness with respect to such Cut
Back Shares under Section 2(c) shall be the 90th day immediately after the Restriction Termination Date.

 

(e)               
Right to Piggyback Registration.

 

                                                                
(i)                       
If at any time following the date of this Agreement that any Registrable Securities remain outstanding (A) there is not
one or more effective Registration Statements covering all of the Registrable Securities and (B) the Company proposes for any reason
to register any shares of Common Stock under the 1933 Act (other than pursuant to a registration statement on Form S-4 or Form
S-8 (or a similar or successor form)) with respect to an offering of Common Stock by the Company for its own account or for the
account of any of its stockholders, it shall at each such time promptly give written notice to the holders of the Registrable Securities
of its intention to do so (but in no event less than thirty (30) days before the anticipated filing date) and, to the extent permitted
under the provisions of Rule 415 under the 1933 Act, include in such registration all Registrable Securities with respect to which
the Company has received written requests for inclusion therein within fifteen (15) days after receipt of the Company’s notice
(a “Piggyback Registration”). Such notice shall offer the holders of the Registrable Securities the opportunity to
register such number of shares of Registrable Securities as each such holder may request and shall indicate the intended method
of distribution of such Registrable Securities.

    	A-4

    	 

    
 

                                                              
(ii)                       
Notwithstanding the foregoing, (A) if such registration involves an underwritten public offering, the Investors must sell
their Registrable Securities to, if applicable, the underwriter(s) at the same price and subject to the same underwriting discounts
and commissions that apply to the other securities sold in such offering (it being acknowledged that the Company shall be responsible
for other expenses as set forth in Section 2(b)) and subject to the Investors entering into customary underwriting documentation
for selling stockholders in an underwritten public offering, and (B) if, at any time after giving written notice of its intention
to register any Registrable Securities pursuant to Section 2(e)(i) and prior to the effective date of the registration statement
filed in connection with such registration, the Company shall determine for any reason not to cause such registration statement
to become effective under the 1933 Act, the Company shall deliver written notice to the Investors and, thereupon, shall be relieved
of its obligation to register any Registrable Securities in connection with such registration; provided, however, that nothing
contained in this Section 2(e)(ii) shall limit the Company’s liabilities and/or obligations under this Agreement, including,
without limitation, the obligation to pay liquidated damages under this Section 2.

 

                                                            
(iii)                       
If, in connection with any underwritten public offering for the account of the Company or for stockholders of the Company
that have contractual rights to require the Company to register shares of Common Stock, the managing underwriter(s) thereof shall
impose a limitation on the number of shares of Common Stock which may be included in a Registration Statement because, in the judgment
of such underwriter(s), marketing or other factors dictate such limitation is necessary to facilitate such offering, then the Company
shall be obligated to include in the Registration Statement only such limited portion of the Registrable Securities with respect
to which each Investor has requested inclusion hereunder as such underwriter(s) shall permit. Any exclusion of Registrable Securities
shall be made pro rata among the Investors seeking to include Registrable Securities in a Registration Statement, in proportion
to the number of Registrable Securities sought to be included by such Investors; provided, however, that the Company shall not
exclude any Registrable Securities unless the Company has first excluded all outstanding securities, the holders of which are not
entitled to inclusion of such securities in the Registration Statement or are not entitled to pro rata inclusion with the Registrable
Securities; and provided further that, after giving effect to the immediately preceding proviso, any exclusion of Registrable Securities
shall be made pro rata with holders of other securities having the right to include such securities in the Registration Statement.

 

3.                 
Company Obligations. The Company will use commercially reasonable efforts to effect the registration of the Registrable
Securities in accordance with the terms hereof, and pursuant thereto the Company will, as expeditiously as possible:

 

(a)               
use commercially reasonable efforts to cause such Registration Statement to become effective and to remain continuously
effective for a period that will terminate upon the earlier of (i) the date on which all Registrable Securities covered by such
Registration Statement as amended from time to time, have been sold, and (ii) the date on which all Registrable Securities covered
by such Registration Statement may be sold without restriction pursuant to Rule 144 by the holders thereof (the “Effectiveness
Period”) and advise the Investors in writing when the Effectiveness Period has expired;

    	A-5

    	 

    
 

(b)              
prepare and file with the SEC such amendments and post-effective amendments to the Registration Statement and the Prospectus
as may be necessary to keep the Registration Statement effective for the Effectiveness Period and to comply with the provisions
of the 1933 Act and the 1934 Act with respect to the distribution of all of the Registrable Securities covered thereby;

 

(c)               
provide copies to and permit counsel designated by the Investors to review each Registration Statement and all amendments
and supplements thereto no fewer than seven (7) days prior to their filing with the SEC and not file any document to which such
counsel reasonably objects;

 

(d)              
furnish to the Investors and their legal counsel (i) promptly after the same is prepared and publicly distributed, filed
with the SEC, or received by the Company (but not later than two (2) Business Days after the filing date, receipt date or sending
date, as the case may be) one (1) copy of any Registration Statement and any amendment thereto, each preliminary prospectus and
Prospectus and each amendment or supplement thereto, and each letter written by or on behalf of the Company to the SEC or the staff
of the SEC, and each item of correspondence from the SEC or the staff of the SEC, in each case relating to such Registration Statement
(other than any portion of any thereof which contains information for which the Company has sought confidential treatment), and
(ii) such number of copies of a Prospectus, including a preliminary prospectus, and all amendments and supplements thereto and
such other documents as each Investor may reasonably request in order to facilitate the disposition of the Registrable Securities
owned by such Investor that are covered by the related Registration Statement;

 

(e)               
use commercially reasonable efforts to (i) prevent the issuance of any stop order or other suspension of effectiveness and,
(ii) if such order is issued, obtain the withdrawal of any such order at the earliest possible moment;

 

(f)               
prior to any public offering of Registrable Securities, use commercially reasonable efforts to register or qualify or cooperate
with the Investors and their counsel in connection with the registration or qualification of such Registrable Securities for offer
and sale under the securities or blue sky laws of such jurisdictions requested by the Investors and do any and all other commercially
reasonable acts or things necessary or advisable to enable the distribution in such jurisdictions of the Registrable Securities
covered by the Registration Statement; provided, however, that the Company shall not be required in connection therewith or as
a condition thereto to (i) qualify to do business in any jurisdiction where it would not otherwise be required to qualify but for
this Section 3(f), (ii) subject itself to general taxation in any jurisdiction where it would not otherwise be so subject but for
this Section 3(f), or (iii) file a general consent to service of process in any such jurisdiction;

 

(g)              
use commercially reasonable efforts to cause all Registrable Securities covered by a Registration Statement to be listed
on each securities exchange, interdealer quotation system or other market on which similar securities issued by the Company are
then listed;

    	A-6

    	 

    
 

(h)              
immediately notify the Investors, at any time prior to the end of the Effectiveness Period, upon discovery that, or upon
the happening of any event as a result of which, the Prospectus includes an untrue statement of a material fact or omits to state
any material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances
then existing, and promptly prepare, file with the SEC and furnish to such holder a supplement to or an amendment of such Prospectus
as may be necessary so that such Prospectus shall not include an untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then
existing;

 

(i)                
otherwise use commercially reasonable efforts to comply with all applicable rules and regulations of the SEC under the 1933
Act and the 1934 Act, including, without limitation, Rule 172 under the 1933 Act, file any final Prospectus, including any supplement
or amendment thereof, with the SEC pursuant to Rule 424 under the 1933 Act, promptly inform the Investors in writing if, at any
time during the Effectiveness Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof,
the Investors are required to deliver a Prospectus in connection with any disposition of Registrable Securities and take such other
actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder; and make available
to its security holders, as soon as reasonably practicable, but not later than the Availability Date (as defined below), an earnings
statement covering a period of at least twelve (12) months, beginning after the effective date of each Registration Statement,
which earnings statement shall satisfy the provisions of Section 11(a) of the 1933 Act, including Rule 158 promulgated thereunder
(for the purpose of this subsection 3(i), “Availability Date” means the 45th day following the end of the fiscal quarter
that includes the effective date of such Registration Statement, except that, if quarter is the last quarter of the Company’s
fiscal year, “Availability Date” means the 90th day after the end of such fiscal year); and

 

(j)                
with a view to making available to the Investors the benefits of Rule 144 (or its successor rule) and any other rule or
regulation of the SEC that may at any time permit the Investors to sell shares of Common Stock to the public without registration,
the Company covenants and agrees to: (i) make and keep public information available, as those terms are understood and defined
in Rule 144, until the earlier of (A) six months after such date as all of the Registrable Securities may be sold without restriction
by the holders thereof pursuant to Rule 144 or any other rule of similar effect or (B) such date as all of the Registrable Securities
shall have been resold; (ii) file with the SEC in a timely manner all reports and other documents required of the Company under
the 1934 Act; and (iii) furnish to each Investor upon request, as long as such Investor owns any Registrable Securities, (A) a
written statement by the Company that it has complied with the reporting requirements of the 1934 Act, (B) a copy of the Company’s
most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q, and (C) such other information as may be reasonably requested
in order to avail such Investor of any rule or regulation of the SEC that permits the selling of any such Registrable Securities
without registration.

    	A-7

    	 

    
 

4.                 
Due Diligence Review; Information. The Company shall make available, during normal business hours, for inspection
and review by the Investors, advisors to and representatives of the Investors (who may or may not be affiliated with the Investors
and who are reasonably acceptable to the Company), all financial and other records, all SEC Filings (as defined in the Purchase
Agreement) and other filings with the SEC, and all other corporate documents and properties of the Company as may be reasonably
necessary for the purpose of such review, and cause the Company’s officers, directors and employees, within a reasonable
time period, to supply all such information reasonably requested by the Investors or any such representative, advisor or underwriter
in connection with such Registration Statement (including, without limitation, in response to all questions and other inquiries
reasonably made or submitted by any of them), prior to and from time to time after the filing and effectiveness of the Registration
Statement for the sole purpose of enabling the Investors and such representatives, advisors and underwriters and their respective
accountants and attorneys to conduct initial and ongoing due diligence with respect to the Company and the accuracy of such Registration
Statement; provided, however, that the Company shall not disclose material nonpublic information to the Investors, or to advisors
to or representatives of the Investors, unless prior to disclosure of such information the Company identifies such information
as being material nonpublic information and provides the Investors, such advisors and representatives with the opportunity to accept
or refuse to accept such material nonpublic information for review and any Investor wishing to obtain such information enters into
an appropriate confidentiality agreement with the Company with respect thereto.

 

5.                 
Obligations of the Investors.

 

(a)               
Each Investor shall furnish in writing to the Company such information regarding itself, the Registrable Securities held
by it and the intended method of disposition of the Registrable Securities held by it, as shall be reasonably required to effect
the registration of such Registrable Securities and shall execute such documents in connection with such registration as the Company
may reasonably request. At least five (5) Business Days prior to the first anticipated filing date of any Registration Statement,
the Company shall notify each Investor of the information the Company requires from such Investor if such Investor elects to have
any of the Registrable Securities included in the Registration Statement. An Investor shall provide such information to the Company
at least two (2) Business Days prior to the first anticipated filing date of such Registration Statement if such Investor elects
to have any of the Registrable Securities included in the Registration Statement.

 

(b)              
Each Investor, by its acceptance of the Registrable Securities, agrees to cooperate with the Company as reasonably requested
by the Company in connection with the preparation and filing of a Registration Statement hereunder, unless such Investor has notified
the Company in writing of its election to exclude all of its Registrable Securities from such Registration Statement.

 

(c)               
Each Investor agrees that, upon receipt of any notice from the Company of either (i) the commencement of an Allowed Delay
pursuant to Section 2(c)(ii) or (ii) the happening of an event pursuant to Section 3(h) hereof, such Investor will immediately
discontinue disposition of Registrable Securities pursuant to the Registration Statement covering such Registrable Securities,
until the Investor is advised by the Company that such dispositions may again be made.

    	A-8

    	 

    
 

6.                 
Indemnification.

 

(a)               
Indemnification by the Company. The Company will indemnify and hold harmless each Investor and its officers, directors,
members, employees and agents, successors and assigns, and each other Person, if any, who controls such Investor within the meaning
of the 1933 Act, against any losses, claims, damages or liabilities, joint or several, to which they may become subject under the
1933 Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are
based upon: (i) any untrue statement or alleged untrue statement or omission or alleged omission of any material fact contained
in any Registration Statement, any preliminary Prospectus or final Prospectus, or any amendment or supplement thereof; (ii) any
blue sky application or other document executed by the Company specifically for that purpose or based upon written information
furnished by the Company filed in any state or other jurisdiction in order to qualify any or all of the Registrable Securities
under the securities laws thereof (any such application, document or information herein called a “Blue Sky Application”);
(iii) the omission or alleged omission to state in a Blue Sky Application a material fact required to be stated therein or necessary
to make the statements therein not misleading; (iv) any violation by the Company or its agents of any rule or regulation promulgated
under the 1933 Act applicable to the Company or its agents and relating to action or inaction required of the Company in connection
with such registration; or (v) any failure to register or qualify the Registrable Securities included in any such Registration
Statement in any state where the Company or its agents has affirmatively undertaken or agreed in writing that the Company will
undertake such registration or qualification on an Investor’s behalf and will reimburse such Investor, and each such officer,
director or member and each such controlling Person for any legal or other expenses reasonably incurred by them in connection with
investigating or defending any such loss, claim, damage, liability or action; provided, however, that the Company
will not be liable in any such case if and to the extent that any such loss, claim, damage or liability arises out of or is based
upon an untrue statement or alleged untrue statement or omission or alleged omission so made in conformity with information furnished
by such Investor or any such controlling Person in writing specifically for use in such Registration Statement or Prospectus.

 

(b)              
Indemnification by the Investors. Each Investor agrees, severally but not jointly, to indemnify and hold harmless,
to the fullest extent permitted by law, the Company, its directors, officers, employees, stockholders and each Person who controls
the Company (within the meaning of the 1933 Act) against any losses, claims, damages, liabilities and expense (including reasonable
attorney fees) resulting from any untrue statement of a material fact or any omission of a material fact required to be stated
in the Registration Statement or Prospectus or preliminary Prospectus or amendment or supplement thereto or necessary to make the
statements therein not misleading, to the extent, but only to the extent that such untrue statement or omission is contained in
any information furnished in writing by such Investor to the Company specifically for inclusion in such Registration Statement
or Prospectus or amendment or supplement thereto. In no event shall the liability of an Investor be greater in amount than the
dollar amount of the proceeds (net of all expenses paid by such Investor in connection with any claim relating to this Section
6 and the amount of any damages such Investor has otherwise been required to pay by reason of such untrue statement or omission)
received by such Investor upon the sale of the Registrable Securities included in the Registration Statement giving rise to such
indemnification obligation.

    	A-9

    	 

    
 

(c)               
Conduct of Indemnification Proceedings. Any Person entitled to indemnification hereunder shall (i) give prompt notice
to the indemnifying party of any claim with respect to which it seeks indemnification and (ii) permit such indemnifying party to
assume the defense of such claim with counsel reasonably satisfactory to the indemnified party; provided that any Person
entitled to indemnification hereunder shall have the right to employ separate counsel and to participate in the defense of such
claim, but the fees and expenses of such counsel shall be at the expense of such Person unless (a) the indemnifying party has agreed
to pay such fees or expenses, or (b) the indemnifying party shall have failed to assume the defense of such claim and employ counsel
reasonably satisfactory to such Person or (c) in the reasonable judgment of any such Person, based upon written advice of its counsel,
a conflict of interest exists between such Person and the indemnifying party with respect to such claims (in which case, if the
Person notifies the indemnifying party in writing that such Person elects to employ separate counsel at the expense of the indemnifying
party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such Person); and provided,
further, that the failure of any indemnified party to give notice as provided herein shall not relieve the indemnifying
party of its obligations hereunder, except to the extent that such failure to give notice shall materially adversely affect the
indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party shall not, in connection
with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any
time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified party, consent to
entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant
or plaintiff to such indemnified party of a release from all liability in respect of such claim or litigation.

 

(d)              
Contribution. If for any reason the indemnification provided for in the preceding paragraphs (a) and (b) is unavailable
to an indemnified party or insufficient to hold it harmless, other than as expressly specified therein, then the indemnifying party
shall contribute to the amount paid or payable by the indemnified party as a result of such loss, claim, damage or liability in
such proportion as is appropriate to reflect the relative fault of the indemnified party and the indemnifying party, as well as
any other relevant equitable considerations. No Person guilty of fraudulent misrepresentation within the meaning of Section 11(f)
of the 1933 Act shall be entitled to contribution from any Person not guilty of such fraudulent misrepresentation. In no event
shall the contribution obligation of a holder of Registrable Securities be greater in amount than the dollar amount of the proceeds
(net of all expenses paid by such holder in connection with any claim relating to this Section 6 and the amount of any damages
such holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission)
received by it upon the sale of the Registrable Securities giving rise to such contribution obligation.

    	A-10

    	 

    
 

7.                 
Miscellaneous.

 

(a)               
Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement
may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent
of the Company and the Required Investors. Any amendment or waiver effected in accordance with this Section 7(a) shall be binding
upon each holder of any Registrable Securities at the time outstanding, each future holder of any Registrable Securities, and the
Company. The Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only
if the Company shall have obtained the written consent to such amendment, action or omission to act, of the Required Investors.

 

9.14         
Notices. All notices and other communications provided for or permitted hereunder shall be made as set forth
in Section 9.4 of the Purchase Agreement.

 

9.15         
Assignments and Transfers by Investors. The provisions of this Agreement shall be binding upon and inure to
the benefit of the Investors and their respective successors and assigns. An Investor may transfer or assign, in whole or from
time to time in part, to one or more Persons its rights hereunder in connection with the transfer of Registrable Securities by
such Investor to such Person, provided that such Investor complies with all laws applicable thereto and provides written notice
of assignment to the Company promptly after such assignment is effected.

 

9.16         
Assignments and Transfers by the Company. This Agreement may not be assigned by the Company (whether by operation
of law or otherwise) without the prior written consent of the Required Investors, provided, however, that in the event that the
Company is a party to a merger, consolidation, share exchange or similar business combination transaction in which the Common Stock
is converted into the equity securities of another Person, from and after the effective time of such transaction, such Person shall,
by virtue of such transaction, be deemed to have assumed the obligations of the Company hereunder, the term “Company”
shall be deemed to refer to such Person and the term “Registrable Securities” shall be deemed to include the securities
received by the Investors in connection with such transaction unless such securities are otherwise freely tradable by the Investors
after giving effect to such transaction.

 

9.17         
Benefits of the Agreement. The terms and conditions of this Agreement shall inure to the benefit of and be
binding upon the respective permitted successors and assigns of the parties. Nothing in this Agreement, express or implied, is
intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies,
obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 

9.18         
Counterparts; Facsimile. This Agreement may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. The exchange of copies of this Agreement
and of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery of this Agreement as
to the Parties and may be used in lieu of an original of this Agreement for all purposes. Signatures of the Parties transmitted
by facsimile or PDF transmission shall be deemed to be their original signatures for all purposes.

    	A-11

    	 

    
 

9.19         
Titles and Subtitles; Construction. The titles and subtitles used in this Agreement are used for convenience
only. They form no part of this Agreement and shall not affect its construction or interpretation. All references to Sections,
subsections, paragraphs, clauses or other subdivisions in this Agreement refer to the corresponding Sections, subsections, paragraphs,
clauses or other subdivisions of this Agreement. All words used in this Agreement shall be construed to be of such gender or number
as the circumstances require. As used in this Agreement, the words “hereby”, “herein”, hereof”, “hereunder”
and words of similar import refer to this Agreement as a whole and not to any particular provision of this Agreement.

 

9.20         
Severability. Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall,
as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining
provisions hereof but shall be interpreted as if it were written so as to be enforceable to the maximum extent permitted by applicable
law, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision
in any other jurisdiction. To the extent permitted by applicable law, the parties hereby waive any provision of law which renders
any provisions hereof prohibited or unenforceable in any respect.

 

9.21         
Further Assurances. The parties shall execute and deliver all such further instruments and documents and take
all such other actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment
of the agreements herein contained.

 

9.22         
Entire Agreement. This Agreement and the Purchase Agreement, together with its Exhibits and Disclosure Schedules,
constitute the entire agreement among the parties hereof with respect to the subject matter hereof and thereof and supersede all
prior agreements and understandings, both oral and written, between the parties with respect to the subject matter hereof and thereof.

 

9.23         
Governing Law; Consent to Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by, and construed
in accordance with, the internal laws of the State of New York without regard to the choice of law principles thereof. Each of
the parties hereto irrevocably submits to the exclusive jurisdiction of the courts of the State of New York located in New York
County and the United States District Court for the Southern District of New York for the purpose of any suit, action, proceeding
or judgment relating to or arising out of this Agreement and the transactions contemplated hereby. Service of process in connection
with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified
for the giving of notices under this Agreement. Each of the parties hereto irrevocably consents to the jurisdiction of any such
court in any such suit, action or proceeding and to the laying of venue in such court. Each party hereto irrevocably waives any
objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim
that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum.  EACH OF THE PARTIES
HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT COUNSEL
HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.

 

 

 

[Signature Pages Follow]

    	A-12

    	 

    
 

IN WITNESS WHEREOF,
the parties have executed this Agreement or caused their duly authorized officers to execute this Agreement as of the date first
above written.

 

	The Company:	CRUMBS BAKE SHOP, INC.
	 	 	 
	 	 	 
	 	 	 
	 	By:	/s/ Julian Geiger
	 	Name:	Julian Geiger
	 	Title:	Chief Executive Officer

 

 

[Investor Signature Page Immediately
Follows]

    	A-13

    	 

    
 

Counterpart
Signature Page

 

 

	FOR ENTITY INVESTORS:	 	FOR INDIVIDUAL INVESTORS:
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	Signature:	 
	[Name of Entity]	 	Name:	 
	 	 	 	 	 
	By:	 	 	 	 
	Name:	 	 	 	 
	Title:	 	 	 	 

 

    	A-14

    	 

    
 

Exhibit A

 

Plan of Distribution

 

The selling stockholders,
which as used herein includes donees, pledgees, transferees or other successors-in-interest selling shares of common stock or interests
in shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership
distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common
stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or
in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices
related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices.

 

The selling stockholders
may use any one or more of the following methods when disposing of shares or interests therein:

 

	 	·	ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
	 	 	 
	 	·	block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction;
	 	 	 
	 	·	purchases by a broker-dealer as principal and resale by the broker-dealer for its account;
	 	 	 
	 	·	an exchange distribution in accordance with the rules of the applicable exchange;
	 	 	 
	 	·	privately negotiated transactions;
	 	 	 
	 	·	short sales effected after the date the registration statement of which this Prospectus is a part is declared effective by the SEC;
	 	 	 
	 	·	through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;
	 	 	 
	 	·	broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share;
	 	 	 
	 	·	a combination of any such methods of sale; and
	 	 	 
	 	·	any other method permitted by applicable law.

 

    	A-15

    	 

    
 

The selling stockholders
may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if
they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of
common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other
applicable provision of the Securities Act amending the list of selling stockholders to include the pledgee, transferee or other
successors in interest as selling stockholders under this prospectus. The selling stockholders also may transfer the shares of
common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling
beneficial owners for purposes of this prospectus.

 

In connection with
the sale of our common stock or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions
they assume. The selling stockholders may also sell shares of our common stock short and deliver these securities to close out
their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling
stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation
of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares
offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus
(as supplemented or amended to reflect such transaction).

 

The aggregate proceeds
to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common stock less
discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together with their agents
from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents.
We will not receive any of the proceeds from this offering.

 

The selling stockholders
also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act of
1933, provided that they meet the criteria and conform to the requirements of that rule.

 

The selling stockholders
and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein may be "underwriters"
within the meaning of Section 2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale
of the shares may be underwriting discounts and commissions under the Securities Act. Selling stockholders who are "underwriters"
within the meaning of Section 2(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities
Act.

 

To the extent required,
the shares of our common stock to be sold, the names of the selling stockholders, the respective purchase prices and public offering
prices, the names of any agents, dealer or underwriter, any applicable commissions or discounts with respect to a particular offer
will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement
that includes this prospectus.

    	A-16

    	 

    
 

In order to comply
with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered
or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified
for sale or an exemption from registration or qualification requirements is available and is complied with.

 

We have advised the
selling stockholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the
market and to the activities of the selling stockholders and their affiliates. In addition, to the extent applicable we will make
copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders for the
purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer
that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under
the Securities Act.

 

We have agreed to indemnify
the selling stockholders against liabilities, including liabilities under the Securities Act and state securities laws, relating
to the registration of the shares offered by this prospectus.

 

We have agreed with the selling stockholders
to keep the registration statement of which this prospectus constitutes a part effective until the earlier of (1) such time as
all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with the registration statement
or (2) the date on which all of the shares may be sold without restriction pursuant to Rule 144 of the Securities Act.

    	A-17

    	 

    
 

EXHIBIT B

ACCREDITED INVESTOR
LETTER

 

October __, 2012

 

Crumbs Bake Shop, Inc.

110 West 40th Street, Suite 2100

New York, NY 10018

 

Ladies and Gentlemen:

 

In connection with the possible purchase
by the undersigned Investor of shares of common stock, par value $.0001 per share (the “Common Stock”), of Crumbs
Bake Shop, Inc. (the “Company”) in a transaction exempt from the registration requirements of the Securities
Act of 1933, as amended (the “1933 Act”), the undersigned Investor makes the following representations and warranties
to the Company:

 

1.The Investor is an “accredited
investor” within the meaning of Rule 501 of Regulation D under the 1933 Act, and has checked the box(es) below which are
next to the category or categories under which the Investor qualifies as an accredited investor:

 

For Individuals

 

 

 ̈A
natural person whose individual net worth, or joint net worth with that person’s spouse, at the time of his purchase exceeds
$1,000,000. For such purposes, the value of one’s primary residence should not be counted as an asset and the amount of the
mortgage on such primary residence, to the extent that it does not exceed the value of the residence, should not be counted as
a liability.

 

 ̈A
natural person with individual income (without including any income of the Investor’s spouse) in excess of $200,000, or joint
income with spouse in excess of $300,000, in each of the two most recent years and who reasonably expects to reach the same income
level in the current year.

 

For Entities

 

 ̈An
entity, including a grantor trust, in which all of the equity owners are accredited investors (for this purpose, a beneficiary
of a trust is not an equity owner, but the grantor of a grantor trust is an equity owner).

 

 ̈A
corporation, Massachusetts or similar business trust, or partnership, not formed for the specific purpose of acquiring Securities,
or an organization described in Section 501(c)(3) of the Internal Revenue Code, with total assets in excess of $5 million.

    	B-1

    	 

    
 

 ̈A
bank as defined in Section 3(a)(2) of the Securities Act, or any savings and loan association or other institution as defined in
Section 3(a)(5)(A) of the Securities Act whether acting in its individual or fiduciary capacity.

 

 ̈An
insurance company as defined in Section 2(a)(13) of the Securities Act.

 

 ̈A
broker-dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934.

 

 ̈An
investment company registered under the Investment Company Act of 1940 (the “Investment Company Act”).

 

 ̈A
business development company as defined in Section 2(a)(48) of the Investment Company Act of 1940.

 

 ̈A
small business investment company licensed by the Small Business Administration under Section 301(c) or (d) of the Small Business
Investment Act of 1958.

 

 ̈A
private business development company as defined in Section 202(a)(22) Of the Investment Advisers Act of 1940.

 

 ̈A
trust with total assets in excess of $5 million not formed for the specific purpose of acquiring Securities, whose purchase is
directed by a person with such knowledge and experience in financial and business matters as to be capable of evaluating the merits
and risks of an investment in the Securities.

 

 ̈An
employee benefit plan within the meaning of ERISA if the decision to invest in the Company is made by a plan fiduciary, as defined
in Section 3(21) of ERISA, which is either a bank, savings and loan association, insurance company, or registered investment adviser,
or if the employee benefit plan has total assets in excess of $5 million or, if a self-directed plan, with investment decisions
made solely by persons that are accredited investors.

 

 ̈A
plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political
subdivisions for the benefit of its employees, if the plan has total assets in excess of $5 million.

 

2.The Investor, if a
natural person, has his or her principal residence in the State of _________________; and, if an entity, has its principal office
in the State of _________________.

    	B-2

    	 

    
 

3.As of the date hereof and prior
to the possible investment, the Investor beneficially owns (as determined pursuant to Rule 13d-3 under the Securities Exchange
Act of 1934, as amended) ____________ shares of the Common Stock.

 

The Investor understands and agrees that
the Company will rely on the foregoing representations and warranties in consummating the possible sale and purchase of the shares.

 

	 	Sincerely yours,
	 	 	 
	 	FOR INDIVIDUAL INVESTORS:
	 	 	 
	 	 	 
	 	Signature:	 
	 	Name:	 
	 	 	 
	 	 	 
	 	FOR ENTITY INVESTORS:
	 	 	 
	 	 	 
	 	 
	 	[Name of Entity]
	 	 	 
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 

 

    	B-3

    	 

    
 

CRUMBS BAKE SHOP, INC. DISCLOSURE SCHEDULES

 

The disclosures made in these Disclosure
Schedules are made pursuant to Section 4 of the attached Securities Purchase Agreement, dated as of October 10, 2012, by and between
Crumbs Bake Shop, Inc. (the “Company”) and each of the Investors identified therein (the “Agreement”).
Capitalized terms used but not defined in these Disclosure Schedules shall have the meanings given such terms in the Agreement.

 

Nothing in these Disclosure Schedules is
intended to broaden the scope of any representation or warranty of the Company contained in the Agreement or to create any covenant
on the part of the Company. Inclusion of any item in these Disclosure Schedules shall not constitute or be deemed to be an admission
to any third party concerning such item by the Company or any Subsidiary.

 

These Disclosure Schedules are arranged
and numbered to correspond with the subsections of Section 4 of the Agreement.

    	 

    	 

    
 

SCHEDULE 4.1 - LIST
OF SUBSIDIARIES

 

Crumbs Holdings LLC, a Delaware limited liability
company

Crumbs 17th Street, LLC, a District
of Columbia limited liability company

Crumbs 42nd Street, LLC, a New
York limited liability company

Crumbs 92nd Street, LLC, a New
York limited liability company

Crumbs Americana, LLC, a California limited
liability company

Crumbs Beverly Hills, LLC, a California limited
liability company

Crumbs Broad Street, LLC, a New York limited
liability company

Crumbs Broadway LLC, a New York limited liability
company

Crumbs Brooklyn Heights LLC, a New York limited
liability company

Crumbs Calabasas, LLC, a California limited
liability company

Crumbs Catering LLC, a New York limited liability
company

Crumbs Clarendon LLC, a Virginia limited liability
company

Crumbs Columbia LLC, a New York limited liability
company (f/k/a Crumbs 125th Street, LLC)

Crumbs Columbus LLC, a New York limited liability
company

Crumbs Douglaston Plaza, LLC, a New York limited
liability company

Crumbs Downtown II, LLC, a New York limited
liability company

Crumbs East Bakeshop II, LLC, a New York limited
liability company

Crumbs East End, LLC, a District of Columbia
limited liability company

Crumbs E-Commerce LLC, a New York limited
liability company

Crumbs Federal Street LLC, a Delaware limited
liability company

Crumbs Garment Center LLC, a New York limited
liability company

Crumbs Grand Central LLC, a New York limited
liability company

Crumbs Greenvale LLC, a New York limited liability
company

Crumbs Greenwich, LLC, a Connecticut limited
liability company

Crumbs Hoboken, LLC, a New Jersey limited
liability company

Crumbs Hollywood LLC, a California limited
liability company

Crumbs Huntington LLC, a New York limited
liability company

Crumbs II, LLC, a New York limited liability
company

Crumbs International Place, LLC, a Delaware
limited liability company

Crumbs L Street, LLC, a District of Columbia
limited liability company

Crumbs Larchmont, LLC, a California limited
liability company

Crumbs LaSalle, LLC, an Illinois limited liability
company

Crumbs L’Enfant Plaza, LLC, a District
of Columbia limited liability company

Crumbs Lexington LLC, a New York limited liability
company

Crumbs Madison LLC, a New York limited liability
company

Crumbs Malibu, LLC, a California limited liability
company

Crumbs Newark LLC, a New Jersey limited liability
company

Crumbs New Canaan, LLC, a California limited
liability company

Crumbs Oak Park, LLC, an Illinois limited
liability company

Crumbs Park Avenue LLC, a New York limited
liability company

Crumbs Park Avenue South, LLC, a New York
limited liability company

Crumbs Queens Center, LLC, a New York limited
liability company

Crumbs Retail Bake Shops, LLC, a Delaware
limited liability company (f/k/a Crumbs Fulton Street, LLC

    	 

    	 

    
 

Crumbs Ridgewood, LLC, a New Jersey limited
liability company

Crumbs Rittenhouse Square, LLC, a Delaware
limited liability company

Crumbs River North, LLC, an Illinois limited liability company

Crumbs Rockville Town Square, LLC, a Delaware limited liability
company

Crumbs Sixth Avenue, LLC, a New York limited liability company

Crumbs South Clark, LLC, an Illinois limited liability company

Crumbs Stamford, LLC, a Connecticut limited liability company

Crumbs Third Avenue LLC, a New York limited
liability company

Crumbs Times Square LLC, a New York limited
liability company

Crumbs Union Square LLC, a New York limited
liability company

Crumbs Union Station LLC, a District of Columbia
limited liability company

Crumbs Wall Street II, LLC, a New York limited
liability company

Crumbs West Madison, LLC, an Illinois limited liability company

Crumbs Westfield LLC, a New Jersey limited liability company

Crumbs Westport, LLC, a Connecticut limited liability company

Crumbs Wholesale II, LLC, a New York limited
liability company

Crumbs Woodbury LLC, a New York limited liability
company

    	 

    	 

    
 

SCHEDULE 4.3 –CAPITALIZATION

 

Capitalization of the Company

 

	 	 	Shares
	Preferred Stock, par value $.0001 per share	 

	 	Authorized	1,000,000
	 	Issued	234,000
	 	Outstanding	234,000
	 	 	 

	 	Potentially Dilutive Securities:	 

	 	 	 
	 	Reserved for issuance to members if Contingency Consideration were to vest(1) (2)(3)	440,000
	 	 	 
	Common Stock, par value $.0001 per share	 

	 	Authorized	100,000,000
	 	Issued(4)	8,940,969
	 	Outstanding	7,346,385
	 	 	 

	 	Potentially Dilutive Securities:	 
	 	 	 

	 	Authorized for issuance pursuant to Equity Incentive Plan	757,795
	 	Issuable upon exercise of outstanding warrants	5,456,300
	 	Reserved for conversion of New Crumbs Class B Exchangeable Units by	 
	 	Crumbs Holdings' members(3)	2,340,000
	 	Reserved for issuance to members upon exchange of Contingency Consideration that could be paid to members if such Contingency Consideration were to vest(1) (2)(3)	4,400,000

 

	1	Contingency Consideration includes 440,000 shares of Series A Voting Preferred Stock (“Series A Stock”) of the Company and 4,400,000 New Crumbs Class B Exchangeable Units (“Class B Units”) of Crumbs Holdings, LLC (“Holdings”). Contingency Consideration will vest upon satisfaction of certain stock price and/or EBIDTA targets as provided in that certain Business Combination Agreement, dated as of January 9, 2011, as amended on each of February 18, 2011, March 17, 2011 and April 7, 2011 (the “Business Combination Agreement”), by and among the Company, 57th Street Merger Sub LLC, Crumbs Holdings, LLC (“Crumbs”), the members of Crumbs set forth on the signature pages thereto (the “Members”), and the representatives of Crumbs and the Member. 

 

	2	In addition to vesting upon reaching the stock price and/or EBIDTA targets, all unvested Contingency Consideration will immediately vest if there is a “Change of Control” of the Company or Holdings. A “Change of Control” will occur if, among other things, a person or group (within the meaning of Rules 13d-3 and 13d-5 under the 1934 Act) (other than any combination of the Permitted Holders or, in the case of Holdings, the Company) shall obtain beneficial ownership (as defined in Rules 13d-3 and 13d-5 under the 1934 Act) or the voting stock of the Company or Holdings representing more than 35% of the voting power of the capital stock of the Company or Holdings entitled to vote for the election of directors of the Company or Holdings other than directly from a Permitted Holder in a transaction where the ultimate purchaser is known to the Permitted Holder. 

  

	3	Class B Units are exchangeable for shares of Common Stock on a one-for-one basis For each 1 Class B Unit that is exchanged, the Member must also surrender 0.1 share of Series A Stock. 

 

	4	Includes 1,594,584 shares held in treasury

 

    	 

    	 

    
 

Registration Rights Agreements

 

The Company is a party to a Registration
Rights Agreement, dated as of November 14, 2011, with Julian R. Geiger pursuant to which it has agreed to register for resale,
under specified conditions, the Registrable Securities (as defined therein) owned, or that may be acquired, by Mr. Geiger.

 

The Company is a party to a Registration
Rights Agreement, dated as of May 5, 2011, with 57th Street General Acquisition Corp., certain members of Holdings,
Morgan Joseph TriArtisan LLC, acting as representative for the initial public offering underwriter holders, and certain service
providers pursuant to which the Company agreed to register for resale, under specified conditions, the Registrable Securities (as
defined therein) that are owned, or may be acquired, by such Persons.

 

Other Rights to Acquire
Securities

 

Pursuant that certain
Exchange and Support Agreement, dated as of May 5, 2011, by and among the Company, Holdings, and the other parties thereto, as
modified by that certain Accession Agreement, dated as of November 14, 2012, by and among the Company, Holdings and Julian R. Geiger,
(a) the Company is entitled to receive New Crumbs Class A Voting Units upon the exchange of the New Crumbs Class B Units by the
holders thereof, (b) the holders of Common Stock will be entitled to certain adjustments in respect of the Common Stock in the
event of certain dilutive actions, issuances or fundamental transactions described therein by Holdings in respect of its New Crumbs
Class B Units, and (c) the holders of New Crumbs Class B Units of Holdings will be entitled to certain adjustments in respect of
the New Crumbs Class B Units in the event of certain dilutive actions, issuances or fundamental transactions described therein
by the Company in respect of the Common Stock.

 

Pursuant to the Amended
and Restated Certificate of Designation in respect of the Company’s Series A Stock, the holders of shares of Series A Stock
will be entitled to certain dividends and distributions in respect of the Series A Stock in the event the Company declares any
dividend or distribution on the Common Stock in shares of Common Stock, Preferred Stock or securities convertible, exercisable
or exchangeable for Common Stock or Preferred Stock, unless such dividend or distribution is approved by the written consent or
affirmative vote of the holders of at least two-thirds of the then outstanding shares of Series A Stock.

 

The Company’s warrants
provide that the number of shares covered thereby and the exercise prices thereof shall be subject to adjustment in the event of
certain changes in the Common Stock by way of stock dividends, split-ups, extraordinary dividends or other similar events.

 

The Company’s Equity
Incentive Plan contemplates that, in the event of any change in the Company’s
corporate capitalization, then the Compensation Committee, in its sole discretion, may make substitutions or adjustments to the
number of shares reserved for issuance under the Amended Plan, the number of shares covered by awards then outstanding under the
Amended Plan, the limitations on awards under the Amended Plan, the exercise price of outstanding options and such other equitable
substitution or adjustments as it may determine appropriate the Compensation Committee may make substitutions or adjustments to
the number of shares of Common Stock reserved for issuance thereunder, the number of shares covered by awards then outstanding
thereunder, the limitations on awards thereunder, the exercise price of outstanding options and such other equitable substitution
or adjustments as it may determine appropriate.

    	 

    	 

    
 

SCHEDULE 4.8 –
MATERIAL ADVERSE CHANGES

 

 

None.

    	 

    	 

    
 

SCHEDULE 4.11 –
TAX MATTERS

 

None.

    	 

    	 

    
 

SCHEDULE 4.15 –
INTELLECTUAL PROPERTY MATTERS

 

The Company monitors trademark usage throughout
the United States and applications filed with the United States Patent & Trademark Office in an effort to stop the use by Persons
other than the Company and its Affiliates of infringing trademarks. Independent bake shops and bakers occasionally adopt a name
that includes the word “crumbs.” When the Company believes that such Person’s use is or may be confusing with
the Company’s brand, the Company either stops such Person’s use or causes such Person to confine its use to products
that are not confusing with the Company’s core products. Certain Persons who began using the word “crumbs” in
their brands prior to the Company’s existence continue to use that name. The Company believes that no use of the “crumbs”
name by any of such Persons has had, or is reasonably likely to have, a Material Adverse Effect.

    	 

    	 

    
 

SCHEDULE 4.17 - LITIGATION

 

The following summary of litigation identifies
legal actions pending against the Company’s Chief Executive Officer, as disclosed in the Quarterly Report of Aéropostale,
Inc. (“Aéropostale”) on Form 10-Q for the quarter ended July 28, 2012, filed with the SEC on August 30, 2012.

 

In October 2011, Julian R. Geiger, in his
capacity as a director of Aéropostale, was named, along with the other directors and certain
officers of Aéropostale, as defendants in the case styled, Bell v. Geiger, et al.,
No. 652931/2011, a shareholder derivative lawsuit filed in New York state court seeking relief derivatively on behalf of Aéropostale.
The action alleges that the defendants breached their fiduciary duties to Aéropostale
between February 3, 2011 and August 3, 2011 by failing to establish and maintain internal controls that would have prevented Aéropostale
from disseminating allegedly false and misleading and inaccurate statements and other information to shareholders, and to manage
and oversee Aéropostale. As a result, the plaintiff alleges that the defendants exposed
Aéropostale to potential liability in the federal securities class action lawsuit styled,
City of Providence, v. Aéropostale, Inc., et al., No. 11-7132, described below.

 

In February 2012, Julian R. Geiger, in
his capacity as a former director of Aéropostale, was named, along with the other current
and former directors and certain officers of Aéropostale, as defendants in the case styled,
The Booth Family Trust v. Meads, et al., No. 650594/2012, a shareholder derivative lawsuit filed in New York state court
seeking relief derivatively on behalf of Aéropostale. As in Bell, this action alleges
that the defendants breached their fiduciary duties to Aéropostale by failing to establish
and maintain internal controls that would have prevented Aéropostale from disseminating
allegedly false and misleading and inaccurate statements and other information to shareholders, and to manage and oversee Aéropostale.
As a result, and as in Bell, the plaintiff alleges that the defendants have exposed Aéropostale
to losses and damages, including civil liability from City of Providence suit.

 

On April 24, 2012, the New York Supreme
Court, New York County, issued an order consolidating and staying the Bell and Booth actions pending a ruling on the motion to
dismiss filed in City of Providence, a class action lawsuit
filed in New York federal court in October 2011 alleging violations of the federal securities laws by certain officers of Aéropostale.

    	 

    	 

    
 

SCHEDULE 4.18 –
UNDISCLOSED LIABILITIES

 

None.

    	 

    	 

    
 

SCHEDULE 4.21 –
FEES TO AGENTS

 

The Company is a party to a letter agreement,
dated as of August 24, 2012, with Janney Scott Montgomery LLC (“Janney”) pursuant to which the Company appointed Janney
as its lead financial advisor and, in connection with the transactions contemplated by this Agreement, agreed to (a) pay Janney
a non-refundable retainer fee of $50,000, which shall be credited toward the advisory fee, (b) pay Janney an advisory fee of 7.00%
of the gross proceeds raised in these transactions, subject to certain exclusions, (c) reimburse Janney for its expenses, up to
$50,000, and (c) indemnify Janney and its affiliates, the directors, officers, employees and agents of Janney and its affiliates,
and each other person or entity, if any, controlling Janney or any of its affiliates within the meaning of Section 15 of the 1933
Act or Section 20 of the 1934 Act from certain losses they suffer in connection with the transactions. In addition, the Company
agreed to pay Janney the advisory fee described above in the event the Company sells, within 12 months following the termination
of the letter agreement, securities similar to the securities covered by this Agreement to a person who was introduced to the Company
by Janney.

 

The Company is a party to a letter agreement,
dated as of August 24, 2012, with Susman Partners LLC d/b/a Threadstone Advisors (“Threadstone”) pursuant to which
the Company agreed to reimburse Threadstone for its expenses, up to $10,000, incurred in acting as a co-advisor to the Company
in connection with these transactions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}]]